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A B S T R A C T
Background
Several clinical trials of vitamin D to prevent asthma exacerbation and improve asthma control have been conducted in children and
adults, but a meta-analysis restricted to double-blind, randomised, placebo-controlled trials of this intervention is lacking.
Objectives
To evaluate the efficacy of administration of vitamin D and its hydroxylated metabolites in reducing the risk of severe asthma exacer-
bations (defined as those requiring treatment with systemic corticosteroids) and improving asthma symptom control.
Search methods
We searched the Cochrane Airways Group Trial Register and reference lists of articles. We contacted the authors of studies in order to
identify additional trials. Date of last search: January 2016.
Selection criteria
Double-blind, randomised, placebo-controlled trials of vitamin D in children and adults with asthma evaluating exacerbation risk or
asthma symptom control or both.
Data collection and analysis
Two review authors independently applied study inclusion criteria, extracted the data, and assessed risk of bias. We obtained missing
data from the authors where possible. We reported results with 95% confidence intervals (CIs).
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Main results
We included seven trials involving a total of 435 children and two trials involving a total of 658 adults in the primary analysis. Of these,
one trial involving 22 children and two trials involving 658 adults contributed to the analysis of the rate of exacerbations requiring
systemic corticosteroids. Duration of trials ranged from four to 12 months, and the majority of participants had mild to moderate
asthma. Administration of vitamin D reduced the rate of exacerbations requiring systemic corticosteroids (rate ratio 0.63, 95% CI
0.45 to 0.88; 680 participants; 3 studies; high-quality evidence), and decreased the risk of having at least one exacerbation requiring
an emergency department visit or hospitalisation or both (odds ratio (OR) 0.39, 95% CI 0.19 to 0.78; number needed to treat for
an additional beneficial outcome, 27; 963 participants; 7 studies; high-quality evidence). There was no effect of vitamin D on %
predicted forced expiratory volume in one second (mean difference (MD) 0.48, 95% CI -0.93 to 1.89; 387 participants; 4 studies;
high-quality evidence) or Asthma Control Test scores (MD -0.08, 95% CI -0.70 to 0.54; 713 participants; 3 studies; high-quality
evidence). Administration of vitamin D did not influence the risk of serious adverse events (OR 1.01, 95% CI 0.54 to 1.89; 879
participants; 5 studies; moderate-quality evidence). One trial comparing low-dose versus high-dose vitamin D reported two episodes of
hypercalciuria, one in each study arm. No other study reported any adverse event potentially attributable to administration of vitamin
D. No participant in any included trial suffered a fatal asthma exacerbation. We did not perform a subgroup analysis to determine
whether the effect of vitamin D on risk of severe exacerbation was modified by baseline vitamin D status, due to unavailability of
suitably disaggregated data. We assessed two trials as being at high risk of bias in at least one domain; neither trial contributed data to
the analysis of the outcomes reported above.
Authors’ conclusions
Meta-analysis of a modest number of trials in people with predominantly mild to moderate asthma suggests that vitamin D is likely to
reduce both the risk of severe asthma exacerbation and healthcare use. It is as yet unclear whether these effects are confined to people
with lower baseline vitamin D status; further research, including individual patient data meta-analysis of existing datasets, is needed to
clarify this issue. Children and people with frequent severe asthma exacerbations were under-represented; additional primary trials are
needed to establish whether vitamin D can reduce the risk of severe asthma exacerbation in these groups.
P L A I N L A N G U A G E S U M M A R Y
Vitamin D to prevent asthma attacks
Review question
Does vitamin D prevent asthma attacks or improve control of asthma symptoms or both?
Background
Low blood levels of vitamin D (the ’sunshine vitamin’) have been linked to an increased risk of asthma attacks in children and adults
with asthma. Several clinical trials have been conducted to test whether vitamin D might prevent asthma attacks and improve control
of asthma symptoms in children and adults, but results from studies with the most scientifically sound designs have not previously been
evaluated as a group.
Included studies
We included seven trials involving 435 children and two trials involving 658 adults in the review from searches run up to January 2016.
Of these, one trial involving 22 children and two trials involving 658 adults contributed to the analysis of the rate of severe asthma
attacks. Study duration ranged from four to 12 months, and the majority of those taking part had mild or moderate asthma. All of the
studies compared vitamin D with placebo.
Key results
People given vitamin D experienced fewer asthma attacks needing treatment with oral steroids. The average number of attacks per
person per year went down from 0.44 to 0.22 with vitamin D (high-quality evidence). Vitamin D reduced the risk of attending hospital
with an acute asthma attack from 6 per 100 to around 3 per 100 (high-quality evidence).
Vitamin D had little or no effect on lung function or day-to-day asthma symptoms (high-quality evidence). We found that vitamin D
did not increase the risk of serious adverse events at the doses that were tested (moderate-quality evidence).
We based all of these findings on studies judged to be of high quality.
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Conclusion
Vitamin D is likely to offer protection against severe asthma attacks. Further trials focusing on children and people who experience
frequent severe asthma attacks are needed before definitive clinical recommendations can be made.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Vitamin D versus placebo for the management of asthma (all studies)
Patient or population: children and adults with predominant ly m ild to moderate asthma
Setting: primary and secondary care
Intervention: vitamin D3 administered orally over study durat ion of 4 to 12 months
Comparison: placebo
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with placebo Risk with vitamin D
Rate rat io, exacerba-
t ions requiring sys-
temic cort icosteroids
assessed with: number
of events per part ici-
pant per year. Follow-
up: 6 to 12 months
Study populat ion RR 0.63
(0.45 to 0.88)
680
(3 RCTs)
⊕⊕⊕⊕
HIGH
Evidence based primar-
ily on adults with mild
to moderate asthma
0.44 events per person
per year1
0.28 events per person
per year (0.20 to 0.39)
People with 1 or more
exacerbat ions requir-
ing ED visit or hospital-
isat ion or both. Follow-
up: 6 to 12 months
Study populat ion OR 0.39
(0.19 to 0.78)
963
(7 RCTs)
⊕⊕⊕⊕
HIGH
Evidence based primar-
ily on children and
adults with mild to mod-
erate asthma63 per 1000 25 per 1000
(13 to 50)
FEV1, % predicted. Fol-
low-up: 6 to 12 months
The mean FEV1, % pre-
dicted was 85.62%
The mean FEV1, % pre-
dicted in the interven-
t ion group was 0.48%
more (0.93 fewer to 1.
89 more)
- 387
(4 RCTs)
⊕⊕⊕⊕2
HIGH
Evidence based primar-
ily on children and
adults with mild to mod-
erate asthma
4
V
ita
m
in
D
fo
r
th
e
m
a
n
a
g
e
m
e
n
t
o
f
a
sth
m
a
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
6
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
ACT/ C-ACT score. Fol-
low-up: 6 to 12 months
The mean ACT/ C-ACT
score was 20 points
The mean ACT/ C-ACT
score in the interven-
t ion group was 0.08
points fewer (0.7 fewer
to 0.54 more)
- 713
(3 RCTs)
⊕⊕⊕⊕2
HIGH
Evidence based primar-
ily on adults with mild
to moderate asthma
People with fatal
asthma exacerbat ion.
Follow-up: 6 to 12
months
Study populat ion Not est imable 963
(7 RCTs)
⊕⊕ 3
LOW
No fatal asthma exacer-
bat ions occurred in in-
cluded studies0 per 1000 0 per 1000
(0 to 0)
People with 1 or more
serious adverse event
due to any cause. Fol-
low-up: 6 to 12 months
Study populat ion OR 1.01
(0.54 to 1.89)
879
(5 RCTs)
⊕⊕⊕
4
MODERATE
Evidence based primar-
ily on children and
adults with mild to mod-
erate asthma
48 per 1000 49 per 1000
(27 to 87)
* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
ACT, Asthma Control Test; C-ACT, Childhood Asthma Control Test; CI, conf idence interval; ED, emergency department; FEV1, forced expiratory volume in one second; OR, odds
rat io; RCT, randomised controlled trial; RR, rate rat io
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
1The event rate in part icipants randomised to placebo was est imated by calculat ing the weighted mean of event rates reported
in placebo arms of included studies.
2Despite null ef fects of the intervent ion on these outcomes, we are conf ident that the true ef fect lies close to the est imates,
as 95% conf idence intervals for these est imates are very narrow.
3Downgraded two levels due to imprecision (no events occurred in included studies).
4Downgraded one level due to imprecision (wide conf idence intervals).
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B A C K G R O U N D
Description of the condition
Asthma is a chronic inflammatory condition of the airways, char-
acterised by recurrent attacks of breathlessness, wheezing, cough,
and chest tightness, commonly termed ’exacerbations’. The preva-
lence of asthma varies widely between countries. In children, the
prevalence of severe asthma symptoms ranges from 0% (India) to
20.3% (Costa Rica) (Lai 2009); in adults, the prevalence of doctor-
diagnosed asthma ranges from 0.2% (China) to 21.0% (Australia)
(To 2012). Exacerbations represent the major cause of morbidity
and mortality in people with asthma (Johnston 2006). Asthma
exacerbations are commonly classified as severe when they require
treatment with systemic corticosteroids and/or when they result
in emergency department attendance, hospitalisation, or death
(Reddel 2009). Common precipitants of asthma exacerbation in-
clude acute respiratory infections and exposure to allergens and
particulates (Singh 2006).
Description of the intervention
Vitamin D is a fat-soluble micronutrient that has two ’parent’
forms: cholecalciferol (vitamin D3) and ergocalciferol (vitamin
D2). Cholecalciferol is synthesised in human skin from its pre-
cursor molecule 7-dehydrocholesterol on exposure to ultraviolet B
(UVB) radiation in sunlight; it may also be ingested, either in the
diet (primarily from eating oily fish or vitamin D-fortified foods)
or as vitaminD supplements. Ergocalciferol is the plant and fungal
form of the vitamin, which may be ingested in the diet (primarily
by eating fungi) or as vitamin D supplements. In situations where
cutaneous exposure to UVB radiation of appropriate intensity is
limited (for example during winter at latitudes above 34ºN or
below 34ºS, or in settings where people do not regularly expose
their skin to sunlight), dietary sources of vitamin D or vitamin D
supplements or both may be required to meet the body’s vitamin
D requirement (Holick 2007).
Following cutaneous synthesis or ingestion, both forms of parent
vitamin D undergo metabolism to form 25-hydroxyvitamin D
(25(OH)D), the major circulating vitamin D metabolite whose
serum concentration indicates vitamin D status. 25-hydroxylation
may occur in the liver and in extra-hepatic tissues, including leu-
cocytes (Holick 2007). Serum 25(OH)D concentrations less than
50 nmol/L are widely accepted to indicate vitamin D deficiency;
concentrations less than 25 nmol/L represent profound deficiency.
Concentrations of 50 to 74 nmol/L may represent a milder state
of inadequate vitamin D status, commonly termed ‘vitamin D
insufficiency’. 25(OH)D undergoes a second hydroxylation step
at the 1-alpha position to form the active vitamin D metabolite
1,25-dihydroxyvitamin D (1,25(OH)2D), the steroid hormone
and active vitamin D metabolite that mediates the biological ac-
tions of vitamin D by binding the vitamin D receptor to regulate
gene expression (Holick 2007). This 1-alpha hydroxylation step is
catalysed by the enzymeCYP27B1, which is expressed inmany tis-
sues including the kidney, leucocytes, and pulmonary epithelium;
expression of CYP27B1 in leucocytes and pulmonary epithelium
is up-regulated in response to infection and inflammation.
This review included studies evaluating the effects of adminis-
tration, by any route and at any dose, of vitamin D3, vitamin
D2, 25(OH)D, or 1,25(OH)2D. Vitamin D3, vitamin D2, and
25(OH)D are usually administered orally; the ‘parent compounds’
vitamin D3 and vitamin D2 may also be given intramuscularly.
Intramuscular administration of a bolus dose of vitamin D in-
duces a slower increase and a lower peak in serum 25(OH)D than
oral administration of the same dose (Romagnoli 2008), conse-
quently this route of administration is not widely employed in
clinical trials of vitamin D. The functional in vivo half-life of
25(OH)D in the circulation is one to two months; accordingly,
it takes at least three months to attain steady-state concentrations
of 25(OH)D in response to daily administration of vitamin D
(Heaney 2003). Due to the relatively long half-life of 25(OH)D,
parent vitamin D and 25(OH)D may be administered intermit-
tently as well as daily; weekly and monthly dosing regimens are
often employed, and more widely spaced dosing regimens are also
sometimes used. However, dosing less frequently than monthly
results in large non-physiological fluctuations in serum 25(OH)D
concentration, which may cause undesirable effects (Hollis 2013;
Martineau 2012; Vieth 2009). The influence of dosing interval
on biological responses to administration of vitamin D is an area
of active research in the field.
How the intervention might work
About 1 billion people worldwide are estimated to have 25(OH)D
levels of less than 75 nmol/L (Holick 2007). Inadequate vitaminD
status has been reported to be common among people with asthma
in a variety of settings. Cross-sectional, Brehm 2012, and co-
hort, Brehm2010 andConfino-Cohen 2014, studies have demon-
strated independent associations between inadequate vitamin D
status and increased risk of exacerbations. Administration of vita-
min D3, vitamin D2, or 25(OH)D results in increased circulating
concentrations of 25(OH)D. This 25(OH)D acts as a substrate
for CYP27B1 expressed in the kidney and multiple extra-renal tis-
sues. Of particular relevance for asthma, CYP27B1 expression in
the airway and leucocytes is induced during infection and inflam-
mation, so that the active vitamin D metabolite 1,25(OH)2D is
synthesised locally in the lung. 1,25(OH)2D ligates the vitamin
D receptor (VDR) to induce antimicrobial activity (for example
by induction of antimicrobial peptide expression), Greiller 2015
and Martineau 2007, and exert anti-inflammatory activity (for
example by induction of the anti-inflammatory cytokine IL-10,
suppression of proinflammatory tumour necrosis factor and inter-
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feron-γ - inducible chemokines, and inhibition of lipopolysaccha-
ride-induced synthesis of reactive oxygen species) (Coussens 2012;
Lan 2014; Mann 2014). This combination of antimicrobial, an-
tiviral, and anti-inflammatory activity might decrease the risk of
exacerbations, which are often precipitated by respiratory infec-
tion and which are characterised by dysregulated pulmonary in-
flammation. Of particular relevance to asthma, 1,25(OH)2D has
been shown to inhibit TH17 cytokine production and enhance
responsiveness to inhaled corticosteroids for production of inter-
leukin-10 ex vivo in people with asthma (Nanzer 2014; Xystrakis
2006). These findings raise the possibility that administration of
vitamin D or 25(OH)D may therefore have a role in reducing ex-
acerbation risk and improving symptom control in combination
with inhaled corticosteroids, as well as independently. However,
controversy exists regarding what serum 25(OH)D concentration,
if any, is optimum for reducing the risk of asthma exacerbations.
Why it is important to do this review
There is considerable interest in the potential of administration of
vitamin D to reduce exacerbation risk and improve asthma symp-
tom control. Several published trials of vitamin D in children with
asthma have reported statistically significant reductions in exacer-
bation rates among children randomised to the intervention arm
(Majak 2011; Urashima 2010; Yadav 2014), two trials in adults
have also reported non-statistically significant trends towards re-
duced exacerbation rates in their intervention arms (Castro 2014;
Martineau 2015). Meta-analysis of these trials has the potential to
increase statistical power to detect effects of administering vitamin
D on exacerbation risk. However, definitions of severe exacerba-
tion differ between trials, and published meta-analyses in the field
have utilised the variable definitions reported in primary publica-
tions rather than adopting a unified definition for this outcome
across studies (Luo 2015; Riverin 2015; Xiao 2015). These meta-
analyses also included some non-placebo-controlled trials (Baris
2014; Darabi 2013), as well as trials of relatively short duration
(less than 12 weeks) (De Groot 2015; Schou 2003). We there-
fore conducted ameta-analysis that was restricted to double-blind,
placebo-controlled trials of at least 12 weeks’ duration to deter-
mine the effect of vitamin D on the primary outcome of exacer-
bation treated with systemic corticosteroids.
O B J E C T I V E S
To evaluate the efficacy of administration of vitamin D and its
hydroxylated metabolites in reducing the risk of severe asthma
exacerbations (defined as those requiring treatment with systemic
corticosteroids) and improving asthma symptom control.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We reviewed double-blind, randomised, placebo-controlled trials
of at least 12 weeks’ duration. We did not include studies focusing
only on bone outcomes, which we considered to provide very lim-
ited insights into asthma morbidity. We included studies reported
as full text and unpublished data. Where eligible studies were pub-
lished as abstracts only, we contacted the authors to request the full
text of the trial report; where full text was unavailable, we listed
such studies as ’ongoing’.
Types of participants
We included children and adults with a clinical diagnosis of
asthma, based on the presence of characteristic symptoms and
signs (wheeze, shortness of breath, chest tightness, or cough) and
variable airflow obstruction. We imposed no restrictions regarding
disease severity, baseline vitamin D status, or duration of treat-
ment with asthma medication.
Types of interventions
The review was open to studies in which vitamin D3, vitamin D2,
25(OH)D, or 1,25(OH)2D was administered at any dose.
Types of outcome measures
Primary outcomes
1. Incidence of severe asthma exacerbations, defined as those
requiring treatment with systemic corticosteroids
Secondary outcomes
1. Incidence of asthma exacerbations precipitating an
emergency department visit or requiring hospital admission or
both
2. End-study Asthma Control Test (ACT) score
3. End-study % predicted forced expiratory volume in one
second (FEV1)
4. Incidence of any severe adverse event, irrespective of
causation
5. Incidence of fatal asthma exacerbation
6. Incidence of asthma exacerbation as defined in the study
protocol
7. End-study % eosinophils in induced sputum or
bronchoalveolar lavage
8. End-study peak expiratory flow rate
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9. Incidence of adverse reactions attributed to administration
of vitamin D or its metabolites
10. Proportion of participants withdrawing from the trial
We would have meta-analysed the following secondary outcomes
had sufficient data been available.
1. Time off school or work due to asthma symptoms
2. Beta2-agonist inhaler use
3. End-study asthma quality of life as judged by use of a
validated instrument
4. End-study fractional exhaled nitric oxide concentration
5. End-study airway reactivity
6. Costs from the perspective of healthcare providers
Search methods for identification of studies
Electronic searches
We identified trials from the Cochrane Airways Group’s Spe-
cialised Register (CAGR), which is maintained by the informa-
tion specialist for the Group. The Register contains trial reports
identified through systematic searches of bibliographic databases
including the Cochrane Central Register of Controlled Trials
(CENTRAL), MEDLINE, EMBASE, CINAHL, AMED, and
PsycINFO, and handsearching of respiratory journals andmeeting
abstracts (please see Appendix 1 for further details). We searched
all records in the CAGR using the search strategy in Appendix 2.
We also conducted searches
of ClinicalTrials.gov (www.ClinicalTrials.gov), the World Health
Organization trials portal (www.who.int/ictrp/en/), the ISRCTN
registry (www.isrctn.com/), the Australian New Zealand Clinical
Trials Registry (www.anzctr.org.au/), and the UMIN Clinical Tri-
alsRegistry (www.umin.ac.jp/ctr/).We searched all databases from
their inception to 6 January 2016, and imposed no restriction on
language of publication.
Searching other resources
We checked reference lists of all primary studies and review arti-
cles for additional references.We searched relevant manufacturers’
websites for trial information.
We searched for errata or retractions from included studies pub-
lished in full text on PubMed (www.ncbi.nlm.nih.gov/pubmed),
but did not find any. We also contacted a panel of international
experts for additional references and information on trials in
progress.
Data collection and analysis
Selection of studies
Two people (Adrian R Martineau (ARM) and either Christopher
J Cates (CJC) or Andrea Takeda (AT)) independently screened for
inclusion the titles and abstracts of all the potentially relevant stud-
ies identified as a result of the search, coding them as ’retrieve’ (el-
igible or potentially eligible/unclear) or ’do not retrieve’. We then
retrieved the full-text study reports/publication, and two people
(ARM and either CJC or AT) independently screened the full text,
identifying studies for inclusion and identifying and recording
reasons for exclusion of the ineligible studies. Any disagreements
were resolved through discussion or by consultation with other
members of the review team (Christopher J Griffiths (CJG) and
Aziz Sheikh (AS)) or both. We identified and excluded duplicates
and collated multiple reports of the same study so that each study,
rather than each report, was the unit of interest in the review. We
recorded the selection process in sufficient detail to complete a
PRISMA flow diagram and ’Characteristics of excluded studies’
table (Moher 2009).
Data extraction and management
We used a data collection form for study characteristics and out-
come data which was piloted on at least one study in the review.
Two review authors (ARM and one of CJC, CJG, and Alex PGrif-
fiths (APG)) extracted study characteristics from each included
study. We extracted the following study characteristics.
1. Methods: study design, total duration of study, details of
any ’run-in’ period, number of study centres and location, study
setting, withdrawals, and date of study.
2. Participants: number, mean age, age range, gender, body
mass index, severity of condition, diagnostic criteria, baseline
lung function, smoking history, inclusion criteria, and exclusion
criteria.
3. Interventions: intervention, comparison, concomitant
medications, and excluded medications.
4. Outcomes: primary and secondary outcomes specified and
collected, and time points reported.
5. Notes: funding for trial, and notable conflicts of interest of
trial authors.
Two review authors (ARM and one of CJC, CJG, and APG) in-
dependently extracted outcome data from each included study. If
outcome data were not reported in a usable way, we noted this
in the ’Characteristics of included studies’ table. We resolved dis-
agreements by consensus or by involving a third person (CJG or
AS). One review author (ARM) transferred data into the RevMan
2015 file. We double-checked that data were entered correctly by
comparing the data presented in the systematic review with the
study reports. A second review author (CJC) checked study char-
acteristics for accuracy against the trial reports.
Assessment of risk of bias in included studies
The ’Risk of bias’ assessment for the study authored by ARM
and CJG, Martineau 2015, was performed by Ulugbek Nurmatov
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(UN) and CJC. For all other studies, two review authors (ARM
and one of CJC and APG) independently assessed the risk of bias
for each study using the criteria outlined in theCochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011).We resolved
any disagreements by discussion or by involving another review
author (AS).We assessed the risk of bias according to the following
domains.
1. Random sequence generation
2. Allocation concealment
3. Blinding of participants and personnel
4. Blinding of outcome assessment
5. Incomplete outcome data
6. Selective outcome reporting
7. Other biases, including study size
We graded each potential source of bias as high, low, or unclear and
provided a quote from the study report together with a justification
for our judgement in the ’Risk of bias’ table. We summarised
the ’Risk of bias’ judgements across different studies for each of
the domains listed. Where information on risk of bias related to
unpublished data or correspondence with a trialist, we noted this
in the ’Risk of bias’ table. When considering treatment effects, we
took into account the risk of bias for the studies that contributed
to that outcome.
Assessment of bias in conducting the systematic
review
We conducted the review according to a published protocol
(Martineau 2015b), and have reported any deviations from it in
the Differences between protocol and review section.
Measures of treatment effect
We analysed event rates as rate ratios (RR), dichotomous data as
odds ratios (OR), and times to first event as hazard ratios (HR).We
analysed other continuous outcome measures as mean difference
(MD) or standardised mean difference (SMD). We used generic
inverse variance meta-analysis where adjusted measures of treat-
ment effect from individual trials were included. We entered data
presented as a scale with a consistent direction of effect. For anal-
yses of outcomes in which no events occurred in some studies, we
also calculated risk differences (RD).We undertook meta-analyses
only where this was meaningful, that is if the treatments, partic-
ipants, and the underlying clinical question were similar enough
for pooling to make sense.
Where multiple trial arms were reported in a single trial, we in-
cluded only the relevant arms. If two comparisons (for example
drug A versus placebo and drug B versus placebo) had been com-
bined in the samemeta-analysis, we would have halved the control
group to avoid double-counting.
For outcomes measured at different time points, we included the
longest time point after randomisation.
Unit of analysis issues
If data had been expressed in unconventional units of analysis, we
would have converted them to conventional units, liaising with
the authors where required.
Dealing with missing data
We contacted investigators or study sponsors in order to verify
key study characteristics and to obtain missing numerical out-
come data where possible. We asked all investigators to provide
data relating to the incidence of fatal asthma exacerbations and
exacerbations requiring treatment with systemic corticosteroids or
emergency department attendance/hospitalisation or both where
these were not reported in the manuscript or abstract.
Assessment of heterogeneity
We used the I2 statistic to measure heterogeneity among the trials
in each analysis. Where we identified substantial heterogeneity (I
2 greater than 40%), we assessed the value of exploring possible
causes by using a prespecified subgroup analysis. However, limita-
tions of the available data (for example where data for participants
within different subgroups could not be disaggregated, or where
numbers of participants or events or both within a subgroup were
small) precluded the conduct of such subgroup analyses.
Assessment of reporting biases
Had we been able to pool more than 10 trials, we would have
created and examined a funnel plot to explore possible small-study
biases.
Data synthesis
Given significant heterogeneity between studies, we used a ran-
dom-effects model for the primary analysis. We performed sensi-
tivity analyses using fixed-effect models for outcomes where the
two models yielded different results. We analysed all data by
intention-to-treat. We synthesised event rates as RRs, dichoto-
mous data as ORs, and times to first event as HRs. We syn-
thesised other continuous outcome measures as MD or SMD.
We calculated the number needed to treat for an additional ben-
eficial outcome (NNTB) using the Visual Rx NNT calculator
(www.nntonline.net/visualrx/) where meta-analysis of dichoto-
mous outcomes revealed a statistically significant beneficial ef-
fect of allocation to vitamin D. We would have similarly calcu-
lated the number needed to treat for an additional harmful out-
come (NNTH) if meta-analysis of dichotomous outcomes had
revealed statistically significant harmful effects of vitamin D. We
used means and standard deviations (SDs) when available. Where
data were not reported we approached the study authors. We
would have extracted values from graphs had study authors not
responded.
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’Summary of findings’ table
We created a ’Summary of findings’ table using the following out-
comes: incidence of asthma exacerbation treated with systemic
corticosteroids; incidence of asthma exacerbation requiring emer-
gency department attendance or hospitalisation for asthma or
both; end-study % predicted FEV1; end-study ACT score; inci-
dence of fatal asthma exacerbation; and incidence of serious ad-
verse events due to any cause. We used the five GRADE consider-
ations (study limitations, consistency of effect, imprecision, indi-
rectness, and publication bias) to assess the quality of the body of
evidence as it related to the studies which contributed data to the
meta-analyses for the prespecified outcomes.Where data from pri-
mary studies conducted by review authors contributed to a given
outcome, the quality of the evidence was assessed by review au-
thors who were not involved with those primary studies (CJC and
AS). We used methods and recommendations described in Sec-
tion 8.5 and Chapter 12 of the Cochrane Handbook for Systematic
Reviews of Interventions, Higgins 2011, using GRADEpro GDT
2014 software. We justified all decisions to down- or upgrade the
quality of studies using footnotes where necessary.
Subgroup analysis and investigation of heterogeneity
We prespecified that we would carry out the following subgroup
analyses for the outcome of exacerbation treated with systemic
corticosteroids (Martineau 2015b).
1. Baseline vitamin D status (e.g. serum 25(OH)D < 50
nmol/L versus ≥ 50 nmol/L).
2. Age (e.g. children aged < 5 years versus 5 to 16 years versus
adults).
3. Severity of asthma and concomitant asthma treatment
being taken (e.g. taking versus not taking inhaled corticosteroids,
taking versus not taking leukotriene receptor antagonists).
4. The dose (e.g. daily equivalent of < 400 IU versus 400 to
2000 IU versus > 2000 IU) and form of vitamin D administered
(e.g. cholecalciferol versus calcitriol).
5. The frequency of administration (e.g. daily versus
intermittent bolus doses).
6. Genetic variation in pathways of vitamin D metabolism,
transport, and signalling (e.g. GC 2/2 versus 2/1 versus 1/1
genotype for the GC polymorphism of the vitamin D binding
protein).
7. Body mass index (e.g. < 25 kg/m2 versus ≥ 25 kg/m2).
However, limitations of the available data (for example where data
for participants within different subgroups could not be disaggre-
gated, or where numbers of participants or events or both within
a subgroup were small) precluded the conduct of such subgroup
analyses.
Had we conducted these subgroup analyses, we would have used
the formal test for subgroup interactions in RevMan 2015.
Sensitivity analysis
We carried out the following sensitivity analyses.
1. Exclusion of publications assessed as being at high risk of
bias in one or more of the following domains: sequence
generation, allocation concealment, blinding, completeness of
outcome data, or selective outcome reporting.
2. Analyses using fixed-effect models were performed for
outcomes where such models yielded results different from those
generated by random-effects models (Table 1).
R E S U L T S
Description of studies
Results of the search
See Figure 1 for full details.
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Figure 1. Study flow diagram.
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We identified a total of 105 references to 78 different studies by
searching the CAGR and an additional three studies by search-
ing clinical trial registries. After removing one duplicate reference,
we screened 107 references to 81 different studies for eligibility.
We excluded 62 studies on the basis of the titles or the abstracts
or both of the associated references. We assessed the remaining
19 studies for eligibility by consulting the full text of associated
references or contacting study authors or both; we then excluded
10 more studies, four of which did not meet eligibility criteria
for inclusion and six of which we classified as ongoing. We have
presented the reasons for excluding potentially relevant studies in
the Characteristics of excluded studies table.
Included studies
See Characteristics of included studies for full details. Nine com-
pleted studies including a total of 1093 participants with asthma
met the inclusion criteria for this review (Castro 2014; Jensen
2016; Lewis 2012; Majak 2009; Majak 2011; Martineau 2015;
Tachimoto 2016; Urashima 2010; Yadav 2014).
Study design
All included studies were double-blind randomised controlled tri-
als with a parallel-group design, open to male and female partic-
ipants of any ethnic background; five were conducted at a sin-
gle centre (Jensen 2016; Lewis 2012; Majak 2009; Majak 2011;
Yadav 2014), and four were multicentre studies (Castro 2014;
Martineau 2015; Tachimoto 2016; Urashima 2010). All studies
recruited in secondary care, and one study also recruited in pri-
mary care (Martineau 2015). Study duration ranged from four
months, in Urashima 2010, to 12 months, in Lewis 2012, Majak
2009, andMartineau 2015. All trials were restricted to individuals
with a physician diagnosis of asthma; two trials additionally based
eligibility on evidence of reversible or variable airway obstruction
(Castro 2014; Martineau 2015). Current treatment with inhaled
corticosteroids was a requirement for three trials (Castro 2014;
Majak 2009; Martineau 2015), and an exclusion criterion for one
trial (Majak 2011); one trial excluded participants who had re-
ceived oral corticosteroid therapy in the year prior to enrolment
(Urashima 2010). All of the remaining trials included at least some
participants who were taking inhaled corticosteroids.
Only one trial included baseline vitamin D status as an eligibil-
ity criterion (Castro 2014, which excluded people with baseline
25(OH)D concentration greater than or equal to 75 nmol/L), but
six trials had exclusion criteria relating to maximum permitted
pre-trial or concomitant supplemental vitamin D intake or both
(Castro 2014; Jensen 2016; Majak 2009; Majak 2011; Martineau
2015; Tachimoto 2016).
Participants
Seven studies involved 435 children (Jensen 2016; Lewis 2012;
Majak 2009; Majak 2011; Tachimoto 2016; Urashima 2010;
Yadav 2014), and two studies involved 658 adults (Castro 2014;
Martineau 2015). Participants were ethnically diverse, reflecting
the broad range of geographic settings: Canada (Jensen 2016),
India (Yadav 2014), Japan (Tachimoto 2016; Urashima 2010),
Poland (Majak 2009;Majak 2011), theUK (Martineau2015), and
the USA (Castro 2014; Lewis 2012). The majority of participants
had mild/moderate asthma, and a minority had severe asthma.
Where measured, mean/median baseline serum 25(OH)D con-
centration ranged from 48 nmol/L, in Castro 2014, to 89 nmol/
L, in Majak 2011; a small minority of participants had serum
25(OH)D concentrations in the profoundly deficient range (less
than 25 nmol/L).
Intervention
All studies administered oral vitamin D3 (cholecalciferol) to par-
ticipants in the intervention arm. There was considerable hetero-
geneity in vitamin D dosage regimens employed. Four studies,
Lewis 2012, Majak 2011, Tachimoto 2016, and Urashima 2010,
used exclusively daily dosing regimens ranging from 500 IU/day,
in Majak 2011, to 1200 IU/day, in Urashima 2010. Of the other
studies, one used weekly dosing (Majak 2009), one used monthly
dosing (Yadav 2014), one used two-monthly dosing (Martineau
2015), and two gave a bolus dose at the start of the study, followed
by daily dosing (Castro 2014; Jensen 2016). One study admin-
istered low-dose vitamin D (400 IU/day) to participants in both
the control arm and intervention arm; participants in the inter-
vention arm of this study received an additional bolus of 100,000
IU vitamin D at the start of the study (Jensen 2016). For the
six trials in which vitamin D was given daily (with or without
additional bolus doses) (Castro 2014; Jensen 2016; Lewis 2012;
Majak 2011; Tachimoto 2016; Urashima 2010), the median daily
dose was 900 IU/day, ranging from 400 IU/day, in Jensen 2016,
to 4000 IU/day, in Castro 2014. Where vitamin D status was as-
sessed, the intervention resulted in an interarm difference in fol-
low-up serum 25(OH)D concentration on at least one follow-up
time point in four studies (Castro 2014; Jensen 2016; Martineau
2015; Tachimoto 2016), but not in three others (Lewis 2012;
Majak 2009; Majak 2011).
Outcomes
Seven trials reported asthma exacerbation as an outcome mea-
sure (Castro 2014; Jensen 2016; Majak 2011; Martineau 2015;
Tachimoto 2016; Urashima 2010; Yadav 2014). Definitions of
exacerbation varied significantly between trials. Authors of seven
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trials provided data on exacerbations requiring treatment with
systemic corticosteroids for the purposes of this review (Castro
2014; Jensen 2016; Majak 2009; Majak 2011; Martineau 2015;
Tachimoto 2016; Urashima 2010).
Excluded studies
See Characteristics of excluded studies for full details.
Risk of bias in included studies
An overview of ’Risk of bias’ judgements is shown in Figure 2.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Two studies did not report the method of sequence generation
(Lewis 2012; Yadav 2014), and two studies did not report the
method of allocation concealment (Lewis 2012;Majak 2011).We
have therefore classified the risk of selection bias for these studies
as ’unclear’. We assessed the risk of selection bias for the remaining
studies as low.
Blinding
It appears that participants and study personnel, including those
who administered the intervention, have been effectively blinded
to allocation for all studies; accordingly, we assessed the risk of
performance and detection bias as low for all studies.
Incomplete outcome data
One-third of participants in the study by Lewis et al were lost
to follow-up (Lewis 2012); we have therefore assessed the risk of
attrition bias as high for this study. The study by Yadav et al reports
that 18 out of 100 participants were lost to follow-up, but follow-
up data for 100 participants was presented for the final follow-
up visit (Yadav 2014). This discrepancy led us to assess the risk of
attrition bias as being high for this study. We assessed the study by
Urashima et al as being at unclear risk of attrition bias (Urashima
2010); although rates of loss were comparable between arms for
this trial as a whole (50 out of 217 intervention arm, 46 out of
213 control arm), they were not reported for the subgroup of
participants with doctor-diagnosed asthma. We assessed the risk
of attrition bias for the remaining studies as low.
Selective reporting
We found no evidence of selective reporting for any of the included
studies, and have therefore assessed the risk of reporting bias as
low for all studies.
Other potential sources of bias
In the study by Yadav et al (Yadav 2014), we noted a marked
change in classification of asthma severity between the six-month
time point and earlier time points. This suggested a high risk of
misclassification bias operating at the final follow-up time point.
We identified no other potential sources of bias for the remaining
included trials.
Effects of interventions
See: Summary of findings for the main comparison Vitamin D
versus placebo for the management of asthma (all studies)
See Summary of findings for the main comparison.
Vitamin D versus placebo: all eligible trials
Nine trials with a total of 1093 participants (435 children and 658
adults) contributed to this comparison for at least one outcome.
Three trials with a total of 680 participants (22 children and 658
adults) contributed to this comparison for analysis of the rate of
exacerbations requiring systemic corticosteroids.
Primary outcome
Asthma exacerbation treated with systemic corticosteroids
Analyses including all participants
Administration of vitamin D was associated with a statistically sig-
nificant reduction in the rate of asthma exacerbations treated with
systemic corticosteroids (RR 0.63, 95% confidence interval (CI)
0.45 to 0.88; 680 participants; 3 studies; high-quality evidence;
Analysis 1.1; Figure 3). We found weaker evidence to suggest a
benefit of vitamin D for the outcomes of time to first such ex-
acerbation (HR 0.69, 95% CI 0.48 to 1.00; 658 participants; 2
studies; moderate-quality evidence; Analysis 1.2) and proportion
of participants experiencing one or more such exacerbation (OR
0.74, 95% CI 0.49 to 1.10; 933 participants; 7 studies; moder-
ate-quality evidence; Analysis 1.3); 95% confidence intervals in-
cluded or spanned 1.00 for these outcomes. Of note, trials con-
ducted in adults contributed a disproportionate amount of data
to these analyses (Castro 2014; Martineau 2015); severe exacer-
bations were only seen in two out of five trials that enrolled chil-
dren (Jensen 2016; Tachimoto 2016), and the total numbers of
such events were small. Also of note, only one child in the trial
by Tachimoto et al experienced such an event (Tachimoto 2016),
therefore RRs and HRs for this study could not be calculated.
Time-to-event data for calculation of HRs were not available for
the other paediatric trial that saw any such events (Jensen 2016).
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Figure 3. Forest plot of comparison: 1 Vitamin D versus placebo (all studies), outcome: 1.1 Rate ratio,
exacerbations requiring systemic corticosteroids.
Subgroup analyses
Lack of access to individual participant data precluded conduct of
prespecified subgroup analyses for the outcome of severe asthma
exacerbation according to baseline vitamin D status, asthma sever-
ity, concomitant asthma treatment, body mass index, and genetic
variation in the vitamin D pathway.
We did not conduct prespecified subgroup analyses for different
age groups (children aged less than 5 years versus 5 to 16 years
versus adults) due to a lack of severe exacerbations arising in trials
that enrolled children. We did not conduct subgroup analyses for
different dosing frequencies as some studies combined bolus and
daily dosing strategies and could not be classified (Castro 2014;
Jensen 2016), and the number of remaining studies within each
subcategory was small. We did not perform subgroup analyses for
different dose sizes due to the small number of studies and events
arising within each subcategory.
All trials investigated effects of vitamin D3, which precluded the
conduct of subgroup analysis by type of vitamin D administered.
Secondary outcomes
Asthma exacerbation precipitating emergency department
visit or requiring hospitalisation or both
Administration of vitamin D was associated with a statistically sig-
nificant reduction in the proportion of participants experiencing
an asthma exacerbation precipitating an emergency department
visit or hospital admission or both (OR 0.39, 95% CI 0.19 to
0.78; NNTB 27, 95% CI 20 to 76; 963 participants; 7 studies;
high-quality evidence; Analysis 1.5; Figure 4). The expected result
in 100 people given vitamin D for an average of 7months is shown
in the Cates plot in Figure 5: in comparison with 6 out of 100
with this outcome on placebo, this fell to 3 out of 100 (95% CI 1
to 5) on vitamin D.
Figure 4. Forest plot of comparison: 1 Vitamin D versus placebo (all studies), outcome: 1.5 People with one
or more exacerbations requiring ED visit or hospitalisation or both.
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Figure 5. In the control group 6 out of 100 people had a visit to ED or hospitalisation over 8 months,
compared to 3 (95% CI 1 to 5) out of 100 on vitamin D.
As only two of the trials conducted in children reported any such
events (Jensen 2016; Tachimoto 2016), results of this analysis were
primarily driven by the findings of the two trials conducted in
adults (Castro 2014; Martineau 2015).
ACT scores
We saw no effect of vitaminD on ACT scores (MD -0.08, 95%CI
-0.70 to 0.54; 713 participants; 3 studies; high-quality evidence;
Analysis 1.6).
FEV1, % predicted
There was no overall effect of vitamin D on % predicted FEV1
(MD 0.48, 95% CI -0.93 to 1.89; 387 participants; 4 studies;
high-quality evidence; Analysis 1.8).We did not include data from
one trial that investigated FEV1 as an outcome measure in this
meta-analysis because absolute values were reported instead of %
predicted values for this study (Castro 2014). Of note, vitamin D
did not influence absolute values of FEV1 in this study (change
in pre-albuterol FEV1 [L] in intervention vs. control arm over the
course of the study: -0.07 [95% CI -0.14 to 0.01] vs. -0.04 [-0.11
to 0.03], P = 0.64).
Serious adverse event, any cause
Administration of vitamin D did not influence the incidence of
serious adverse events of any cause (OR1.01, 95%CI 0.54 to 1.89;
879 participants; 5 studies; I2 = 0%; moderate-quality evidence;
Analysis 1.9)
Fatal asthma exacerbations
No participant in any of the included trials suffered a fatal asthma
exacerbation, therefore we saw no effect of the intervention on
this outcome (RD 0.00, 95% CI -0.01 to 0.01; 963 participants;
7 studies; I2 = 0%; low quality evidence; Analysis 1.7).
Asthma exacerbation as defined in primary trial protocols
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The definitions of asthma exacerbations used in individual trials
are summarised in Table 2. Administration of vitamin D reduced
the risk of experiencing at least one such exacerbation (OR 0.53,
95% CI 0.28 to 0.99; NNTB 9, 95% CI 6 to 483; 999 partic-
ipants; 7 studies; moderate-quality evidence; Figure 6; Analysis
1.10), but there was considerable heterogeneity in study defini-
tions of exacerbation, and I2 was high (65%). The expected result
in 100 people given vitamin D for an average of 8months is shown
in the Cates plot in Figure 7: in comparison with 29 out of 100
with this outcome on placebo, this fell to 18 out of 100 (95% CI
10 to 29) on vitamin D.
Figure 6. Forest plot of comparison: 1 Vitamin D versus placebo (low risk of bias), outcome: 1.10 People
with one or more study-defined exacerbations.
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Figure 7. In the control group 29 out of 100 people had a study-defined exacerbation over 7 months,
compared to 18 (95% CI 10 to 29) out of 100 on Vitamin D.
Lower airway eosinophilia
Vitamin D did not influence mean eosinophil count in the lower
airway (MD -0.38, 95% CI -1.92 to 1.15; 525 participants; 3
studies; high-quality evidence; Analysis 1.11).
Peak expiratory flow rate
Vitamin D did not influence mean end-study peak expiratory
flow rate (MD 3.16, 95% CI -13.40 to 19.72; 302 participants;
2 studies; high-quality evidence; Analysis 1.12).
Adverse reaction to vitamin D
Two participants in one trial experienced hypercalciuria (Jensen
2016), an adverse event that is recognised as an adverse reaction to
vitamin D; this event arose in one participant in the intervention
arm and one participant in the control arm of a study inwhich low-
dose vitamin D was administered in both arms. No other study
reported episodes of hypercalciuria or any other adverse events
potentially attributable to administration of vitamin D.
Withdrawals
We saw no difference in the proportion of participants withdraw-
ing from trials between intervention and control arms, but the
confidence intervals were wide (OR 1.07, 95% CI 0.73 to 1.58;
1093 participants; 9 studies; moderate-quality evidence; Analysis
1.14).
Time off school or work
One trial conducted in adults investigated the outcome of work
absence due to asthma exacerbation or upper respiratory infection
(Martineau 2015). Allocation to vitamin D did not influence such
work absencewhenmeasured as time tofirst event (adjusted hazard
ratio 0.77, 95% CI 0.53 to 1.10), event rate (adjusted rate ratio
0.86, 95% CI 0.50 to 1.46), or proportion of participants with at
least one such absence (adjusted odds ratio 0.77, 95% CI 0.45 to
1.30). No trial conducted in children investigated the outcome of
time off school due to asthma symptoms.
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Use of inhaled beta2-agonists
One trial conducted in adults investigated the effects of vitamin
D on the number of uses of inhaled relief medication per 24 hours
(Martineau 2015). Allocation to vitamin D did not influence this
outcome at 12 months (adjusted ratio of geometric means 1.00,
95% CI 0.77 to 1.28).
Asthma quality of life
Two trials conducted in adults investigated the effects of vitamin
D on respiratory quality of life. Martineau et al reported that ad-
ministration of vitamin D modestly improved respiratory quality
of life as evidenced by adjusted interarm differences in total St
George’s Respiratory Questionnaire (SGRQ) score of -3.9 points
at 2 months (P = 0.005), -3.7 points at 6 months (P = 0.038),
and -3.3 points at 12 months (P = 0.060; P for allocation-time
interaction = 0.026). These reductions were associated with sta-
tistically significant decreases in component scores for the impacts
dimension of the SGRQ at two months (P = 0.05) and six months
(P = 0.005; P for allocation-time interaction = 0.030) (Martineau
2015). Of note, the minimum clinically important difference for
this score is around 4 points (Jones 2005). Castro et al reported
no effect of the intervention on the Asthma Bother Profile score:
the adjusted mean change in score was -1.0 (95% CI -2.7 to 0.7)
in the intervention arm versus -2.4 (95% CI -4.0 to -0.7) in the
placebo arm; P = 0.16) (Castro 2014). Data from these two dif-
ferent instruments were unsuitable for pooling and were therefore
not meta-analysed.
Fractional exhaled nitric oxide concentration (FeNO)
One trial conducted in adults investigated the effects of vitamin D
on FeNO.Martineau et al reported that administration of vitamin
D had no effect on mean FeNO concentrations at 12 months
(ratio of geometric means−1.4, 95% CI−6.8 to 3.9) (Martineau
2015).
Other immunological biomarkers of asthma control
One trial conducted in adults investigated the effects of vitamin
D on concentrations of inflammatory markers in induced sputum
supernatants. Martineau et al reported that administration of vi-
tamin D had no effect on supernatant concentrations of a panel of
17 inflammatory markers whose concentrations were detectable,
measured at 2 and 12 months (Martineau 2015). Another trial
conducted in adults investigated the effects of vitamin D on func-
tion of myeloid cells and CD4+ Tcells in peripheral blood, but
found no effect (Castro 2014).
Airway reactivity
One trial conducted in adults investigated the effects of vitamin
D on airway reactivity. Castro et al reported that administration
of vitamin D had no effect on the provocative concentration of
methacholine at which FEV1 decreased by 20% (PC20): the ad-
justed mean change in log base 2 transformed PC20 (doubling
dilutions) was 0.70 (95% CI 0.38 to 1.03) in the intervention arm
versus 0.74 (95% CI 0.41 to 1.07) in the placebo arm; P = 0.87
(Castro 2014).
Costs from the perspective of healthcare providers
One trial conducted in adults investigated the effects of vitamin
D on health economic outcomes. Martineau et al reported that
administration of vitamin D had no effect on total costs associ-
ated with asthma/upper respiratory infection over 12 months (ad-
justed mean difference GBP 66.78, 95% CIGBP -263.47 to GBP
397.03).
Vitamin D versus placebo: sensitivity analysis
excluding trials at high risk of bias
Neither of the two trials assessed as being at high risk of bias con-
tributed data relating to incidence of exacerbation treated with
systemic corticosteroids or exacerbation precipitating emergency
department attendance or hospitalisation or both. One trial as-
sessed as being at high risk of bias reported effects of vitamin D on
the proportion of participants experiencing at least one study-de-
fined exacerbation (Yadav 2014). When this trial was excluded in
a sensitivity analysis, the effect of vitamin D on this outcome was
no longer statistically significant (OR 0.64, 95% CI 0.34 to 1.21;
899 participants; 6 studies; moderate-quality evidence; Analysis
2.1).
Both trials assessed as being at high risk of bias reported effects of
vitaminD on the proportion of participants withdrawing from the
trial (Lewis 2012; Yadav 2014). When these trials were excluded
in a sensitivity analysis, the effect of vitamin D on this outcome
remained null (OR 1.17, 95% CI 0.73 to 1.88; 963 participants;
7 studies; I2 = 7%; moderate-quality evidence; Analysis 2.2).
Vitamin D versus placebo: sensitivity analysis using
fixed-effect model
Random-effects and fixed-effect models yielded non-identical but
similar results for seven secondary outcomes. Results of analyses
performed using each model are presented in Table 1
D I S C U S S I O N
Summary of main results
This systematic review and meta-analysis incorporated evidence
from 435 children and 658 adults participating in nine double-
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blind, randomised, placebo-controlled trials of vitamin D supple-
mentation; of these, one trial involving 22 children and two tri-
als involving 658 adults contributed to the analysis of the rate of
exacerbations requiring systemic corticosteroids. Administration
of vitamin D resulted in a clinically and statistically significant
reduction in the rate of asthma exacerbations requiring treatment
with systemic corticosteroids (RR 0.63, 95%CI 0.45 to 0.88; 680
participants; 3 studies; high-quality evidence; we define a clini-
cally significant reduction in an adverse outcome as being one that
patients and clinicians consider large enough to justify a change
in treatment). Administration of vitamin D also resulted in a clin-
ically and statistically significant reduction in the risk of asthma
exacerbations resulting in emergency department attendance or
hospitalisation or both (OR 0.39, 95% CI 0.19 to 0.78; 963 par-
ticipants; 7 studies; high-quality evidence). Of note, only two of
the trials conducted in children reported any severe exacerbations
(Jensen 2016; Tachimoto 2016), and both of these trials were rel-
atively small (22 and 89 participants, respectively). Accordingly,
results of this analysis were primarily driven by the findings of the
two trials conducted in adults (Castro 2014; Martineau 2015). It
should also be noted that three out of seven studies for which data
on emergency department attendance or hospitalisation or both
were available did not report any such events (Majak 2009; Majak
2011; Urashima 2010).
In contrast to the protective effects demonstrated against severe
exacerbation, we saw no effect of vitamin D on ACT score (MD
-0.08, 95% CI -0.70 to 0.54; 713 participants; 3 studies; high-
quality evidence) or % predicted FEV1 (MD 0.48, 95% CI -
0.93 to 1.89; 387 participants; 4 studies; high-quality evidence).
Vitamin D did not influence the risk of any serious adverse event,
although the 95% confidence interval for this outcome was wide
(OR 1.01, 95% CI 0.54 to 1.89; 879 participants; 5 studies; I2
= 0%; moderate-quality evidence). No fatal asthma exacerbations
were reported in any trial included in this meta-analysis.
Overall completeness and applicability of
evidence
This review incorporated evidence from a relatively modest num-
ber of studies, and results should not be generalised to patient
populations who are not represented. Specifically, there is a relative
lack of evidence on the effects of vitamin D in people with severe
asthma, as evidenced by the modest number of exacerbations re-
sulting in emergency department attendance or hospitalisation or
both, and the absence of fatal exacerbations. This caveat applies
particularly to the studies enrolling children: only 13 of the 305
children included in analysis of the primary outcome experienced
an exacerbation that was treated with systemic corticosteroids, as
compared with 118 of 628 adults. Consequently, the finding that
vitamin D protected against severe asthma exacerbation is based
primarily on results of trials conducted in adults, and therefore
should not be generalised to paediatric populations. Moreover, the
review does not provide evidence about optimum vitamin D doses
and circulating 25(OH)D concentrations.
This review was limited to the inclusion of aggregate data from
published manuscripts, which prevented us from conducting any
of the subgroup analyses prespecified in the study protocol. Con-
sequently we are unable to comment on whether effects of the
intervention are modified by factors such as asthma severity or
baseline vitamin D status. Populations with proven profound vi-
tamin D deficiency (serum 25(OH)D less than 25 nmol/L) were
also poorly represented in the studies eligible for inclusion in this
review; this is particularly significant given that baseline vitamin
D status may modify the effects of administering vitamin D on
exacerbation risk, a phenomenon that has been reported in peo-
ple with chronic obstructive pulmonary disease (Lehouck 2012;
Martineau 2015a). Conversely, a trend towards increased risk of
exacerbationwhen vitaminD is given to those with higher baseline
vitamin D status has been reported (Janssens 2013; Martineau
2015a). Further research to clarify whether baseline vitamin D sta-
tus modifies effects of vitamin D on exacerbation risk, including
individual patient datameta-analysis of existing datasets, is needed
before definitive clinical recommendations can be made.
Despite these reservations regarding external validity, there is less
reason to doubt the internal validity of our findings: these are based
on double-blind, placebo-controlled trials assessed as being at low
risk of bias. Moreover, we found effects of vitamin D on risk of
exacerbation to be consistent when this outcome was expressed in
different ways (RR (Analysis 1.1) versus HR (Analysis 1.2) versus
OR (Analysis 1.3)), and when different definitions of exacerba-
tion were used (exacerbations treated with systemic corticosteroids
(Analysis 1.1) versus those defined according to study protocols
(Analysis 1.10)). For outcomes where vitamin D was found not to
have an effect (% predicted FEV1, ACT score), 95% confidence
intervals were narrow (Analysis 1.8; Analysis 1.6), effectively rul-
ing out a clinically important effect in the populations studied.
The contrast between favourable effects of vitamin D on exacer-
bation versus null effects of this intervention on other measures
of asthma control is striking, and it has implications for choice
of outcome measures in future trials. Given that the majority of
asthma exacerbations are precipitated by viral upper respiratory
infections (Johnston 2006), it seems likely that vitamin D’s mech-
anism of action relates either to prevention of such infections, or
to interruption of pathways by which such events trigger exacer-
bations (Greiller 2015).
Quality of the evidence
This review was restricted to double-blind, placebo-controlled tri-
als; consequently, we assessed all included studies as being at low
risk of performance bias and detection bias. We assessed two stud-
ies as being at high risk of bias in at least one domain. As neither
of these studies contributed data to the primary outcome of this
meta-analysis, the evidence contributing to analysis of the effects
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of vitamin D on risk of severe asthma exacerbation can be regarded
as of high quality. The quality of the evidence relating to adverse
event outcomes was lower. Specifically, evidence regarding fatal
exacerbations was downgraded two levels to ’low’ due to impreci-
sion, as no such events occurred in any included study. Evidence
relating to incidence of serious adverse events was downgraded one
level due to ’moderate’ for imprecision, as confidence intervals for
the pertinent odds ratio were relatively wide (0.54 to 1.89).
Potential biases in the review process
We searched multiple databases for eligible studies using prespec-
ified criteria, and this strategy led to identification of unpub-
lished data which are included in this review. As for any review of
randomised controlled trials, publication bias may have favoured
publication of trials reporting favourable results of vitamin D on
asthma outcomes. The total number of studies included in this
review is relatively modest, and we identified a further six eligi-
ble trials that are ongoing; a repetition of the review in the short
to medium term will determine whether or not promising results
from meta-analysis of early trials are reinforced by subsequent
studies.
Agreements and disagreements with other
studies or reviews
We are aware of three other systematic reviews that have synthe-
sised evidence from randomised controlled trials of vitamin D in
people with asthma.
The study by Riverin et al (Riverin 2015) included data from eight
trials in children, five of which we included in our review (Lewis
2012; Majak 2009; Majak 2011; Urashima 2010; Yadav 2014)
and three of which we excluded either on the grounds that they
were not placebo controlled (Baris 2014; Darabi 2013), or be-
cause duration of follow-up was less than 12 weeks (Schou 2003).
Data from Tachimoto et al (Tachimoto 2016), included in this
meta-analysis, were not included in Riverin 2015. Riverin 2015
reported a reduction in risk of study-defined asthma exacerbation
with vitamin D (RR 0.41, 95% CI 0.27 to 0.63; 378 participants;
3 studies), which was deemed of low quality. No effect of the in-
tervention was seen on asthma symptom scores or lung function.
The study by Luo et al included data from seven trials in both
children and adults (Luo 2015), four of which we included in our
review, and three of which we excluded on the grounds that they
did not report asthma control outcomes (Worth 1994), they were
not placebo controlled (Baris 2014), or because duration of follow-
up was less than 12 weeks (De Groot 2015). Luo et al excluded
four studies included in our review (Lewis 2012; Majak 2011;
Tachimoto 2016;Urashima 2010). Thismeta-analysis reported no
effect of vitamin D on risk of study-defined asthma exacerbation
(RR 0.66, 95% CI 0.32 to 1.37; 820 participants; 3 studies).
The study by Xiao et al focused primarily on effects of vitamin
D on risk of acute respiratory infection (Xiao 2015), but it also
investigated risk of asthma exacerbation in children as a secondary
outcome. This analysis included only two trials (Majak 2011;
Urashima 2010), which reported a protective effect of vitamin D
against “asthma exacerbation triggered by respiratory infection”
(RR 0.28, 95% CI 0.12 to 0.64; 2 studies; n not reported).
The findings of our study seem to be in keeping with those of
Riverin 2015 and Xiao 2015, but contrast with those of Luo 2015.
Disparities in results may be attributable to the inclusion of dif-
ferent primary trials in the different meta-analyses. In addition,
the other meta-analyses used heterogeneous definitions of asthma
exacerbation, as defined by the primary trial, rather than imposing
a universal definition (exacerbation treated with systemic corticos-
teroids), as we did.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
We found a clinically and statistically significant protective effect
of vitamin D against severe exacerbation of asthma and no con-
vincing evidence of an increase in serious adverse events. We be-
lieve that caution is warranted in applying this evidence to clinical
practice because our results come from relatively few trials, none
of which has individually reported a statistically significant effect
of vitamin D on risk of exacerbation requiring treatment with sys-
temic corticosteroids as a prespecified outcome. Trials predomi-
nantly enrolled people with mild or moderate asthma, therefore
those with severe asthma are under-represented. Additionally, tri-
als in children made a relatively minor contribution to findings of
the review relating to severe exacerbations. Consequently, particu-
lar caution should be taken in generalising our findings to people
who have recurrent severe asthma exacerbations and to those aged
less than 16 years.
Furthermore, it is not yet clear whether beneficial effects of admin-
istering vitamin D are experienced by all people with asthma, or
whether this result is driven by favourable effects that are confined
to particular subgroups (for example those with lower baseline vi-
tamin D status, or frequent exacerbations). Studies in chronic ob-
structive pulmonary disease have shown a trend towards increased
risk of exacerbation when vitamin D is given to those with higher
baseline vitamin D status (Janssens 2013; Martineau 2015a). Fur-
ther research to clarify this issue, including individual patient data
meta-analysis of existing datasets, is needed before definitive clin-
ical recommendations can be made.
Implications for research
As discussed above, meta-analysis of individual patient data from
the trials included in this reviewmay potentially elucidate clinically
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significant subgroup effects. Such a project is ongoing (AVID-
Asthma IPDMA), with results expected later in 2016.
We highlight that the optimum vitamin D dose or circulating
25(OH)D level that protects against asthma exacerbations is as yet
unknown and requires additional primary studies to determine.
There is also a need for new primary randomised controlled trials
in populations that are under-represented in the current review,
specifically in vitamin D-deficient children and adults who expe-
rience recurrent severe exacerbations. Eligibility criteria should be
guided by findings of subgroup analyses from individual patient
data meta-analysis, which may reveal groups who are more likely
to experience benefit or harm from the intervention than others.
Our review suggests that such studies are more likely to find effects
of vitamin D on exacerbations requiring treatment with systemic
corticosteroids than on other outcome measures. These studies
should measure participants’ vitamin D status both at baseline and
at follow-up to allow determination of whether effects of admin-
istering vitamin D are dependent on baseline or attained serum
25(OH)D concentrations or both.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Castro 2014
Methods Randomised, double-blind, placebo-controlled, parallel-group trial
Multicentre, 28 weeks long
4-week run-in period, prior asthma treatments discontinued
48 dropped out from study due to consent withdrawal, treatment failure, and asthma-
related adverse event
Analysed by intention-to-treat
Participants 9 academic medical centres in the USA, AsthmaNet network
Predominantly white/black with some Hispanic and Asian
N = 408. 130 m, 278 f. Mean age 39.7 yrs
Inclusion criteria:
1. 18 years or older with asthma and a serum 25-hydroxyvitamin D level of less than
30 ng/mL.
Asthma entry criteria:
1. Physician-diagnosed disease.
2. Evidence of either bronchodilator reversibility (FEV1 ≥ 12% following 180 µg
(4 puffs) of levalbuterol) or airway hyper-responsiveness (PC20 ≤ 8 mg/mL).
Exclusion criteria:
1. Taking vitamin D supplements containing > 1000 IU/day of vitamin D or
supplements containing > 2500 mg/day calcium.
2. Chronic oral corticosteroid therapy.
3. Chronic inhaled corticosteroid therapy > 1000 mcg of fluticasone daily or the
equivalent.
4. New allergen immunotherapy within the past 3 months.
5. History of physician-diagnosed nephrolithiasis or ureterolithiasis.
6. History of life-threatening asthma within the last 5 years.
7. Use of concomitant medications that alter vitamin D metabolism.
8. Impaired renal function (GFR < 30 ml/min) at visit 1.
9. Asthma exacerbation within past 4 weeks requiring systemic corticosteroids.
10. Respiratory tract infection within past 4 weeks.
11. Chronic diseases (other than asthma) that would prevent participation in the trial.
12. History of smoking in the past year.
13. Use of investigative drugs or enrolment in intervention trials in the 30 days prior
to screening.
14. Serum calcium greater than 10.2 mg/dl on entry (at visit 1).
15. Urine calcium/creatinine ratio (mg) > 0.37 (at visit 1).
16. More than 8 weeks elapsed between visit 0 (screen) and visit 2 (evaluated at visit
2).
Interventions Treatment (n = 201): Oral vitamin D3, 100,000 IU bolus once, then 4,000 IU/day for
28 weeks, added to inhaled ciclesonide (320 µg/d)
Control (n = 207): Placebo soft gelatin capsulesmatching in appearance, added to inhaled
ciclesonide (320 µg/d)
Median 25(OH)D concentration at baseline: 47 nmol/L. Mean serum 25(OH)D con-
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Castro 2014 (Continued)
centration, intervention arm: 105 nmol/L (12 weeks), 107 nmol/L (20 weeks), 105
nmol/L (28 weeks)
Outcomes Primary outcome:
Time to first asthma treatment failure.
Treatment failure defined as 1 or more of the following:
1. peak expiratory flow of 65% or less of baseline measurement on 2 of 3
consecutive measurements.
2. FEV1 of 80% or less of baseline measurement on 2 consecutive measurements.
3. Increase in levalbuterol dose of 8puffs/d or more for 48 hours (vs baseline).
4. Additional use of inhaled corticosteroids or use of oral or parenteral
corticosteroids for asthma; emergency department or hospitalisation for asthma with
systemic corticosteroid use.
5. participant lack of satisfaction with treatment; and physician clinical judgment
for safety reasons.
Secondary outcomes:
1. Lung function measures. FEV1 (litres and % predicted)
2. Asthma symptoms (ASUI)
3. Exacerbations
4. Asthma-specific quality of life using Asthma Brother Profile
5. Impairment from asthma, in terms of productivity loss and activity
6. Impairment. Using Work Productivity and Activity Impairment questionnaire
(WPAI: Asthma)
7. Pharmacogenetics. Potential genetic modifiers of response to corticosteroids and
Vitamin D
8. Vitamin D levels. Initial and post-randomisation vitamin D levels compared to
asthma outcomes.
9. Corticosteroid responsiveness. Change in lung function in corticosteroid
unresponsive and responsive individuals evaluated. Corticosteroid-responsive airflow
obstruction defined as a ≥ 5% improvement in FEV1 following systemic
corticosteroids
10. Total inhaled corticosteroid dose
Notes Grants awarded by the National Heart and Lung Institute.
Ciclesonide and levalbuterol were provided without cost by Sunovion Pharmaceuticals
Inc
The National Institutes of Health (NIH) program officers participated in the
design and conduct of the study, and did not participate in the collection, management,
analysis, and interpretation of the data
The authors have completed and submitted the ICMJE Form for Disclosure of Potential
Conflicts of Interest
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random sequence
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Castro 2014 (Continued)
Allocation concealment (selection bias) Low risk Study was “double-masked” and active and
placebo capsules were matched in appear-
ance. Randomisation code was held by the
Data Co-ordinating Centre; the Data Sa-
fety Monitoring Board oversaw the trial
and reviewed data as the trial progressed in
aggregate (group A and B) then unblinded
at the end. Allocation was kept concealed
until the last participant completed the trial
(information from trial report and princi-
pal investigator)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double blind, placebo controlled
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double blind, placebo controlled
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low rates ofwithdrawal overall, whichwere
seen equally between study arms (17/201
in active arm vs 23/207 in control arm dis-
continued the study)
Selective reporting (reporting bias) Low risk No suggestion of selective outcome report-
ing; outcomes detailed in Methods were
reported in Results. However, we did not
have access to the original protocol
Other bias Low risk Nil
Jensen 2016
Methods Single-centre, double-blind, randomised, placebo-controlled trial of 6months’ duration.
Concomitant asthma medications were not discontinued during the trial, and analysis
was by intention-to-treat. Therewas no run-in period.The trial was a pilot study, powered
to compare the proportion of participants achieving serum 25(OH)D concentration
≥ 75 nmol/L. Target enrolment was 17 per arm, actual enrolment was 11 per arm;
enrolment was discontinued on receipt of funding for the substantive trial for which this
was the pilot
Participants Participants (n = 22) were recruited from the asthma clinic, hospital wards, and emer-
gency department of the Sainte-Justine University Health Centre, Montreal, Canada,
and randomised to intervention vs control arms of the study in equal numbers. Baseline
characteristics were well matched, other than an excess of eczema among participants
randomised to vitamin D3 vs placebo.
Inclusion criteria:
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Jensen 2016 (Continued)
1. Age 1 to 5 years.
2. Physician-diagnosed asthma, based on clinical signs of airflow obstruction and
reversibility.
3. URTIs as the main exacerbation trigger, reported by parents.
4. ≥ 4 parent-reported URTIs in the past 12 months.
5. ≥ 1 exacerbation requiring oral corticosteroids in the past 6 months or ≥ 2 in the
past 12 months.
Exclusion criteria:
1. Extreme prematurity (< 28 weeks’ gestation).
2. “High risk of vitamin D deficiency”.
3. Other chronic respiratory disease.
4. Disordered calcium or vitamin D metabolism.
5. Oral medications interfering with vitamin D metabolism.
6. Vitamin D supplementation greater than 1000 IU/day in the past 3 months.
Interventions Active intervention (n = 11): 100,000 IU vitamin D3 oral bolus at baseline, followed by
400 IU vitamin D3 IU orally daily.
Control intervention (n = 11): oral placebo at baseline, followed by 400 vitamin D3 IU
orally daily.
Mean serum 25(OH)D concentration, intervention arm: 62 nmol/L (baseline), 157
nmol/L (10 days)
Outcomes Primary outcome:
The mean group change in total serum 25(OH)D from baseline to 3 months
Secondary outcomes:
1. The proportion of children with total 25(OH)D ≥ 75 nmol/L (30 ng/mL) at 3
months and in total 25(OH)D values over 6 months.
2. The proportion of children with hypercalciuria (urinary calcium: creatinine ratio
(Ca:Cr) > 1.25 (1 to 2 years) and > 1 (2 to 5 years) mmol/mmol) at any time point.
3. Serum calcium, phosphorus, and alkaline phosphatase (ALP).
4. Event rates for exacerbations requiring rescue oral corticosteroids (documented in
medical or pharmacy records or both).
Notes Note that low-dose vitamin D was administered to participants in both intervention and
control arms of this trial. Unpublished full text obtained from corresponding author. No
conflict of interest identified. Funding: Thrasher Research Fund
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random sequence
Allocation concealment (selection bias) Low risk Group assignment, recorded on a sequen-
tially numbered list, was allocated by
the Sainte-Justine Hospital Research Phar-
macy, which held the randomisation code.
Tomaintain blinding, the intervention and
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placebo dose were identical in colour, ap-
pearance, volume, taste, and packaging. All
research personnel, physicians, nurses, par-
ticipants and their parents were blinded to
group allocation. The code was not broken
until the study trial was complete (infor-
mation from principal investigator)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double blind, placebo controlled
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double blind, placebo controlled
Incomplete outcome data (attrition bias)
All outcomes
Low risk 21/22 participants were included in analy-
sis of primary outcome
Selective reporting (reporting bias) Low risk All prespecified primary and secondary
outcomes were reported in the main paper.
All exploratory/additional outcomes were
also reported, with the exception of the du-
ration of exacerbations and viral infections
and the severity of exacerbations (due to
poor questionnaire completion rate, as well
as space restrictions for the manuscript).
The additional outcome of cytokine profile
is to be reported separately (information
from principal investigator; original study
protocol was not obtained)
Other bias Low risk Nil. Information on risk of bias for this trial
relates to unpublished data
Lewis 2012
Methods Randomised, double-blind, placebo-controlled, parallel-group trial (pilot study)
Single-centre, 12 months long
Run-in period not described
Concomitant medication: current daily controller asthma medication
10 dropped out of study (reasons not provided)
Analysis by intention-to-treat not specified
Participants Omaha, Nebraska, USA
Majority black/Hispanic
N = 30, sex distribution not described m/f, age range 6 to 17 yrs
Inclusion criteria:
1. Children < 18 years old.
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2. Physician diagnosis of chronic persistent asthma and current daily controller
asthma medication.
Exclusion criteria:
1. Not described.
Interventions Treatment (n = 15): Oral vitamin D3, 1000 IU/d for 12 months.
Control (n = 15): Placebo (specifications not given) daily for 12 months
Study dates not described.
Mean serum25(OH)Dconcentration, intervention arm: 30 nmol/L (baseline), 68 nmol/
L (6 months, summer), 70 nmol/L (12 months, winter). All 25(OH)D concentrations
above estimated from figure
Outcomes Primary outcomes:
1. ACT score at baseline, 6 and 12 months.
2. Spirometry (FEV1) at baseline, 6 and 12 months.
3. Serum 25(OH)D levels were measured at baseline, 6 and 12 months.
Seconday outcomes:
Not given.
Notes Disclosures: Authors have nothing to disclose.
Funding sources: Funding provided by LB595 State of Nebraska Tobacco Settlement
funds to Creighton University
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of sequence generation not de-
scribed
Allocation concealment (selection bias) Unclear risk No details provided
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind, placebo-controlled trial
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind, placebo-controlled trial
Incomplete outcome data (attrition bias)
All outcomes
High risk High rates of loss to follow-up (10/30 par-
ticipants)
Selective reporting (reporting bias) Low risk No suggestion of selective outcome report-
ing: results were reported for outcomes
listed as having been investigated in the
study report. However, we did not have ac-
cess to the original protocol
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Other bias Low risk Nil
Majak 2009
Methods Randomised, double-blind, placebo-controlled, parallel-group trial
Single-centre, 12 months long
Concomitant medication was continued except: inhaled long-acting beta2-agonists,
leukotriene modifiers, beta-blockers, multivitamin supplements, and systemic corticos-
teroids
Run-in period: September 2005 to March 2006
Analysed on ITT basis
Participants Lodz, Poland
Polish nationals
Total N = 54
N = 36 used for data extraction, 22 m, 14 f. Age range 6 to 12 yrs
Inclusion criteria:
1. Children aged 6 to 12 yrs.
2. IgE-dependent asthma with regular symptoms requiring long-term treatment
with inhaled corticosteroids.
3. A disease duration of at least 2 years.
4. Sensitised only to house dust mites.
Exclusion criteria:
1. Poor understanding of a diary used to record daily symptoms.
2. Lack of ability to perform reproducible spirometry, exhibiting the resting FEV1 of
at least 70%.
3. No contraindications for SIT.
4. Sensitisation to allergens other than house dust mites.
5. Previously received immunotherapy.
Interventions Treatment (n = 18): SIT with prednisone 20 mg + oral vitamin D3, 1000 IU/week for
3 months.
Control (n = 18): SIT with prednisone 20 mg + placebo for 3 months
SITwith placebo only group (n = 18)was not included as did not allowdirect comparison
of effect of vitamin D
Study dates: April 2006 to April 2007.
Mean serum25(OH)Dconcentration, intervention arm: 80 nmol/L (baseline), 82 nmol/
L (3 months)
Outcomes Primary outcomes:
Inhaled steroid-sparing effect of SIT (dose reduction).
Secondary outcomes:
1. Clinical outcomes: Asthma symptom score and FEV1.
2. Immunological outcomes: IL-10, TGF-b1, IL-13, IL-5.
3. 25(OH)D.
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Majak 2009 (Continued)
Notes This study was funded by grant 502-12-760 and 503-2056-1 from the Medical Univer-
sity of Lodz, Poland
No conflict of interest to declare
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated sequence
Allocation concealment (selection bias) Low risk Active intervention drugs and placebowere
blinded by the hospital pharmacy. The
double-blind code was not revealed until
the end of the study
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double blind, placebo controlled
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Doube blind, placebo controlled
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low rates of loss to follow-up, equal be-
tween study arms (1/18 for D3 + steroid
arm vs 1/18 for steroid arm)
Selective reporting (reporting bias) Low risk No suggestion of selective outcome report-
ing: outcomes listed in Methods are re-
ported in Results. However, we did not
have access to the trial protocol
Other bias Low risk Nil
Majak 2011
Methods Randomised, double-blind, placebo-controlled, parallel-group trial
Single-centre, 6 months long
Run-in period: 6 months, concomitant medication discontinued
No drop-out, all participants completed follow-up
Participants Lodz, Poland
Mainly Polish nationals
N = 48. 32 m, 16 f. Mean age 11.5 yrs, range 5 to 18 yrs
Inclusion criteria:
1. Children (5 to 18 yrs) with newly diagnosed asthma.
2. Sensitive only to house dust mites.
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Majak 2011 (Continued)
Exclusion criteria:
1. Treatment with an oral, inhaled, or intranasal corticosteroid.
2. Supplementation with vitamin D during the 6 months preceding the trial.
3. History of fractures in the last 2 years.
4. Previous immunotherapy.
5. Obesity (body mass index > 30 kg/m2).
6. Other chronic diseases.
Interventions Treatment (n = 24): budesonide 800 mg daily administered as a dry inhaled powder and
oral vitamin D3 500 IU daily.
Control (n = 24): budesonide 800 mg daily administered as a dry inhaled powder and
oral placebo daily
Mean serum25(OH)Dconcentration, intervention arm: 90 nmol/L (baseline), 94 nmol/
L (6 months)
Outcomes Primary outcomes:
1. ATAQ symptom score.
2. Lung function (FEV1).
3. Number of exacerbations.
Secondary outcome:
Serum vitamin D status at various time points.
Notes Supported by grant nos. 502-12-760 and 503-2056-1 from the Medical University of
Lodz, Poland.
Disclosure of potential conflict of interest: The authors have declared that they have no
conflict of interest
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random sequence
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double blind, placebo controlled
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double blind, placebo controlled
Incomplete outcome data (attrition bias)
All outcomes
Low risk 100% follow-up
Selective reporting (reporting bias) Low risk Nil to suggest selective reporting: results
were reported for outcomes listed as having
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been investigated in the study report.How-
ever, we did not have access to the original
protocol
Other bias Low risk Nil
Martineau 2015
Methods Randomised, double-blind, placebo-controlled, parallel-group trial
Multicentre, 12 months long
Run-in period: At least 2 weeks, concomitant medication continued
31 did not complete: 17 withdrew consent, 13 lost to follow-up, and 1 died
Study analysed on ITT basis
Participants London, UK
Majority (202/250) white British
N = 250. 109 m, 141 f. Mean age 47.9 yrs
Inclusion criteria:
Medical-record diagnosis of asthma treated with ICS.
Exclusion criteria:
1. Aged 80 years or above.
2. Tobacco smoking history > 15 pack-years.
3. Medical-record diagnosis of COPD.
4. Failure to exhibit significant variability/reversibility in airway obstruction.
Interventions Treatment (n = 125): six 2-monthly oral doses of 6 mL Vigantol oil (Merck Serono,
Darmstadt, Germany) containing 3 mg (120,000 IU) vitamin D3.
Control (n = 125): six 2-monthly oral doses of 6 mL organoleptically identical placebo
(Miglyol oil, Caesar & Loretz, Hilden, Germany)
Mean serum 25(OH)D concentration, intervention arm: 50 nmol/L (baseline), 61.2
nmol/L (2 months), 69.4 nmol/L (12 months)
Outcomes Primary outcomes:
1. Time to first severe asthma exacerbation.
2. Time to first URTI.
Secondary outcomes:
1. Peak values and areas under the curve for symptom scores during severe
exacerbation/URTI.
2. Proportion of days with poor asthma control.
3. Proportion of nights with awakenings due to asthma symptoms.
4. Time to unscheduled healthcare attendance and use of antibiotics for
exacerbation/URTI.
5. ACT and SGRQ scores.
6. FeNO concentration.
7. Daily ICS doses.
8. % predicted FEV1, PEFR.
9. Use of inhaled relief medication and induced sputum differential cell count and
supernatant inflammatory profiles at 2, 6, and 12 months.
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Martineau 2015 (Continued)
10. Serum concentrations of 25(OH)D and parathyroid hormone (PTH) at 2
months and 12 months.
11. Health economic outcomes (costs of exacerbations and URTI, quality-adjusted
life years, and incremental net benefit over 1 year).
Notes Funded by the National Institute for Health Research’s Programme Grants for Applied
Research Programme (ref RP-PG-0407-10398)
No competing interests to declare
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random sequence
Allocation concealment (selection bias) Low risk Randomisation was performed by man-
ufacturer (Nova Laboratories). Manufac-
turer and independent data monitoring
committee held copies of the randomisa-
tion code, which was not revealed to inves-
tigators until database lock at the end of
the trial. All personnel involved in recruit-
ment andmedication delivery were blinded
to randomisation (information from trial
report and principal investigator)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind, placebo-controlled trial
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind, placebo-controlled trial
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants contributed data to analy-
sis of co-primary outcomes. Rates of loss to
follow-up were comparable between arms
(8/125 in intervention arm vs 5/125 con-
trol arm)
Selective reporting (reporting bias) Low risk Results of all analyses specified in protocol
and relating to asthma control are reported;
results of analyses relating to symptoms of
allergic rhinitis will be reported elsewhere.
We had access to the study protocol
Other bias Low risk Nil
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Tachimoto 2016
Methods Randomised, double-blind, placebo-controlled, parallel-group trial
Multicentre, 6 months long
Run-in period: Not described, concomitant medication continued
No drop-out, all participants completed follow-up
Study analysed on ITT basis
Participants Tokyo, Japan
Predominantly Japanese
N = 89. 50 m, 39 f. Mean age 9.9 yrs
Inclusion criteria:
1. Children aged 6 to 15 years at entry.
2. Diagnosed and treated for asthma by 3 collaborating paediatricians of this trial
who were blinded to vitamin D or placebo treatment.
3. Diagnosed according to Global Initiative for Asthma (GINA).
Exclusion criteria:
1. Already taking a vitamin D supplement.
2. History of hospital admission due to respiratory syncytial virus infection,
respiratory treatment by intubation, or urinary tract stone or underlying disease related
to calcium or bone.
3. Underlying chronic disease other than asthma including fracture, mental
retardation, or swallowing disturbance.
4. Other difficulties judged by the paediatrician in charge.
Interventions Treatment (n = 54): vitamin D3 800 IU/day orally for 2 months.
Control (n = 39): daily oral placebo for 2 months.
Mean serum25(OH)Dconcentration, intervention arm: 71 nmol/L (baseline), 86 nmol/
L (2 months), 77 nmol/L (6 months)
Outcomes Primary outcome:
Changes in asthma control levels defined by GINA.
Secondary outcomes:
1. Assessed changes in asthma control levels judged by the childhood ACT (C-ACT)
for children aged 6 to 11 years or the ACT for children aged 12 to 15 years.
2. Changes in Scoring Atopic Dermatitis (SCORAD) between the intervention
groups.
3. Subjective visual analog scales of pruritus and sleep loss for the last 3 days or
nights, summed by the equation: (Extent/5 + Intensity*7/2 + Visual analog scale).
4. Improvement in pulmonary function: Forced vital capacity % predicted (FVC %)
, FEV1%, FEV1/FVC ratio (%), and PEFR%.
5. Total IgE and allergen-specific IgE.
6. Serum levels of IL10, IL13, and IL17A.
Notes This study was supported by the Ministry of Education, Culture, Sports, Science and
Technology in the Japan-Supported Program for the Strategic Research Foundation
at Private Universities and the Jikei University School of Medicine as well by JSPH
KAKENHI Grant Number: 23591553 KAKENHI.
All the authors declare no conflicts of interest
Risk of bias
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Tachimoto 2016 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random sequence
Allocation concealment (selection bias) Low risk Person performing blinding had no clin-
ical involvement in the trial. Randomisa-
tion code was kept by independent data
management committee and was not re-
vealed to staff or participants until the trial
was complete (information from trial re-
port and principal investigator)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind, placebo-controlled study
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind, placebo-controlled study
Incomplete outcome data (attrition bias)
All outcomes
Low risk No withdrawals
Selective reporting (reporting bias) Low risk Nil to suggest selective reporting: outcomes
listed in Methods are reported in Results.
However, the trial protocol was not ac-
cessed
Other bias Low risk Nil. Information on risk of bias for this trial
relates to unpublished data
Urashima 2010
Methods Randomised, double-blind, placebo-controlled, parallel-group trial
Multicentre, 24 weeks long
Run-in period: Not described, concomitant medication continued
96 were lost to follow-up, no reasons provided
Study analysed on ITT basis
Participants 12 hospitals in Japan
N = 430. 242 m, 188 f. Mean age 10.2 yrs, range 6 to 15 yrs
Number with diagnosed asthma: 110
Inclusion criteria:
1. Schoolchildren aged 6 to 15 yrs.
2. With or without underlying diseases.
Exclusion criteria:
1. Had a history of stones in the urinary tract or diseases of calcium or bone
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Urashima 2010 (Continued)
metabolism.
2. Was already taking vitamin D3 or activated vitamin D as a treatment of an
underlying disease.
3. Had a history of allergic reactions to ingredients in the tablets.
4. Had difficulties swallowing tablets.
5. Had been receiving immunosuppressive therapy including oral corticosteroids or
chemotherapy within the past year.
6. Were considered incapable of taking part in the study by the paediatrician in
charge.
Interventions Treatment (n = 217): 3 tablets twice daily (total: 1200 IU vitamin D3/day).
Control (n = 213): 3 tablets twice daily (placebo tablets identical in appearance)
Those with asthma on treatment n = 51.
Those with asthma on placebo n = 59.
Vitamin D status not assessed
Outcomes Primary outcome:
Influenza A, diagnosed by influenza antigen testing.
Secondary outcomes:
1. Influenza B diagnosed via nasopharyngeal swab.
2. Physician-diagnosed asthma attack that included wheezing improved by
inhalation of a beta-stimulant in children who already had a diagnosis of asthma.
3. Non-specific febrile infection in those who were not suspected to have influenza
as well as other specific diseases.
4. Gastroenteritis with 2 of 3 symptoms (nausea or vomiting, diarrhoea, or fever >
37ºC).
5. Pneumonia diagnosed with chest X-ray.
6. Admission to the hospital for any reason.
Notes Funded by the Jikei University School of Medicine.
None of the authors had any conflicts of interest
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated sequence
Allocation concealment (selection bias) Low risk Allocation was concealed from staff and
participants. Randomisation code was kept
by independent datamanagement commit-
tee and was not revealed to staff or partic-
ipants until the trial was complete (infor-
mation from trial report and principal in-
vestigator)
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Urashima 2010 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind, placebo-controlled study
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind, placebo-controlled study
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Rates of loss comparable between arms for
the trial as a whole (50/217 intervention
arm, 46/213 control arm), but not reported
for subgroup of participants with doctor-
diagnosed asthma
Selective reporting (reporting bias) Low risk Nil to suggest selective reporting: outcomes
listed in Methods are reported in Results.
However, the trial protocol was not ac-
cessed
Other bias Low risk Nil
Yadav 2014
Methods Randomised, double-blind, placebo-controlled, parallel-group trial
Single-centre, 6 months long
Run-in period: Not described, concomitant medication continued
18 were lost to follow-up, reasons not provided
Study analysed by intention-to-treat
Participants Rohtak, India
Indian
N = 100. 49 m, 51 f. Mean age 9.6 yrs, range 5 to 13 yrs
Inclusion criteria:
1. Children aged between 3 and 14 yrs.
2. With moderate to severe asthma as per Global Initiative for Asthma (GINA)
guidelines, diagnosed by a physician.
Exclusion criteria:
1. Children on immunotherapy or anti-IgE.
2. History of premature birth (< 36 weeks).
3. Home use of oxygen.
4. Children with non-wheezy asthma and clinical features of vitamin D deficiency
(bony deformities and hypocalcaemic symptoms).
Interventions Treatment (n = 50): oral vitaminD3 (cholecalciferol) 60,000 IUpermonth for 6months.
Control (n = 50): placebo powder in the form of glucose sachet
Vitamin D status not assessed
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Yadav 2014 (Continued)
Outcomes Primary outcome:
Change in the level of asthma severity according to GINA guidelines
Secondary outcomes:
1. Number of exacerbations during treatment period.
2. Change in the PEFR.
3. Change in steroid dosage.
4. Level of control.
5. Emergency visits.
Notes No details on funding provided.
Authors declare no conflict of interest
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of sequence generation not re-
ported
Allocation concealment (selection bias) Low risk Allocation concealed in opaque envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind, placebo-controlled trial
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind, placebo-controlled trial
Incomplete outcome data (attrition bias)
All outcomes
High risk 10/50 children in control arm and 8/50 in
active arm were lost to follow-up, but data
for these ’lost’ children are presented at the
6-month time point (end of study)
Selective reporting (reporting bias) Low risk Nil to suggest selective reporting: outcomes
listed in Methods are reported in Results.
However, we did not have access to the trial
protocol
Other bias High risk Marked change in classification of asthma
severity between 6-month time point and
earlier time points suggests likelihood of
misclassification bias operating at end-
study time point
25(OH)D, 25-hydroxyvitamin D; ACT, Asthma Control Test; ASUI, Asthma Symptom Utility Index; ATAQ, Asthma Therapy
Assessment Questionnaire; COPD, chronic obstructive pulmonary disease; FeNO, fractional exhaled nitric oxide concentration;
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FEV1, forced expiratory volume in one second; GFR, glomerular filtration rate; ICS, inhaled corticosteroids; IgE, immunoglobulin
E; ITT, intention to treat; IU, international unit (40 IU vitamin D = 1 microgram vitamin D); PC20, provocative concentration of
methacholine at which FEV1 decreased by 20%; PEFR, peak expiratory flow rate; SCRG, St George’s Respiratory Questionnaire;
SIT, specific immunotherapy; URTI, upper respiratory tract infection.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Alansari 2015 Not placebo controlled
Arshi 2014 Not placebo controlled
Bantz 2015 Single-blind study
Bar Yoseph 2015 Duration < 12 weeks
Baris 2014 Not placebo controlled
Breitenbuecher 2012 Duration < 12 weeks
Darabi 2013 Not placebo controlled
De Groot 2015 Duration < 12 weeks
Goldring 2013 Primary prevention study
Lakatos 2000 Bone outcomes only
Litonjua 2014 Primary prevention study, protocol only
McDonald 2006 Bone outcomes only
Menon 2014 Not placebo controlled
Nanzer 2014 Duration < 12 weeks
Price 2015 Duration < 12 weeks
Rajanandh 2015 Not placebo controlled
Schou 2003 Duration < 12 weeks
Thijs 2011 Duration < 12 weeks
Torres 2013 Duration < 12 weeks
Utz 1976 Duration < 12 weeks
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(Continued)
Worth 1994 Bone outcomes only
Yemelyanov 2001 Bone outcomes only
Characteristics of ongoing studies [ordered by study ID]
NCT01419262
Trial name or title Vitamin D Outcomes and Interventions In Toddlers
Methods Double-blind, placebo-controlled RCT
Participants Children aged 1 to 5 years
Interventions 2000 vs 400 IU vitamin D3 orally daily
Outcomes Upper respiratory infections (primary), asthma exacerbations in subgroup (secondary)
Starting date September 2011
Contact information Dr Jonathon Maguire, St Michael’s Hospital, Toronto, Canada
Notes
NCT01728571
Trial name or title LungVITamin D and OmegA-3 Trial
Methods Double-blind, placebo-controlled RCT
Participants Adults aged 50 years or older
Interventions 2000 IU vitamin D3 orally daily (factorial design with marine omega-3 fatty acids)
Outcomes Asthma exacerbations and symptoms in subgroup
Starting date July 2010
Contact information Prof Diane Gold, Brigham and Women’s Hospital, Boston, USA
Notes
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NCT02197702
Trial name or title Vitamin D in Preschoolers With Viral-induced Asthma (NCT02197702)
Methods Double-blind, placebo-controlled RCT
Participants Children aged 1 to 5 years with physician-diagnosed asthma
Interventions Vitamin D (100,000 IU) given in a 2 ml oral dose at baseline and 3.5 months
Outcomes Proportion of children with ≥ 1 asthma exacerbation requiring rescue oral corticosteroids
Starting date September 2014
Contact information Francine M Ducharme, St Justine’s Hospital, Montreal, Canada
Notes
NCT02424552
Trial name or title Effect of Vitamin D as add-on Therapy for Vitamin D Insufficient Patients With Severe Asthma
Methods Double-blind, placebo-controlled RCT
Participants Adults with physician-diagnosed severe asthma
Interventions 100,000 IU vitamin D3 bolus, followed by 4000 IU daily, both orally
Outcomes Corticosteroid dose (primary), asthma exacerbations (secondary)
Starting date June 2015
Contact information Dr Stephanie Korn, Johannes Gutenberg University, Mainz, Germany
Notes
NCT02428322
Trial name or title Trial of Vitamin D3 Supplementation in Paediatric Asthma
Methods Double-blind, placebo-controlled RCT
Participants Children aged 6 to 16 years with physician-diagnosed asthma
Interventions 2000 IU vitamin D3 orally daily
Outcomes Paediatric ACT (primary)
Starting date October 2013
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NCT02428322 (Continued)
Contact information Dr Basil Elnazir, National Children’s Hospital, Dublin, Ireland
Notes
Patella 2013
Trial name or title Vitamin D3 associated to lactobacillus reuteri improves effects of allergen immunotherapy in asthmatic
children
Methods Double-blind, placebo-controlled RCT
Participants Children with asthma and house dust mite allergy, age not stated
Interventions Vitamin D, dose not stated
Outcomes Asthma symptoms, FeNO, “medication scores”
Starting date Not reported
Contact information Prof Vincenzo Patella, Agropoli Hospital, Agropoli, Italy
Notes Information from published abstract only
UMIN000004160
Trial name or title A randomized, double blind, comparative study of vitamin D3 versus placebo in small children with asthma
to prevent asthma attack
Methods Double-blind, placebo-controlled RCT
Participants Children aged 2 to 5 years with physician-diagnosed asthma
Interventions 600 IU vitamin D3 orally daily
Outcomes Asthma exacerbations, C-ACT score
Starting date October 2010
Contact information Prof Mitsuyoshi Urashima, Jikei University School of Medicine, Tokyo, Japan
Notes
ACT, Asthma Control Test; C-ACT, Childhood Asthma Control Test; FeNO, fractional exhaled nitric oxide; IU, international unit
(40 IU vitamin D = 1 microgram vitamin D); RCT, randomised controlled trial.
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D A T A A N D A N A L Y S E S
Comparison 1. Vitamin D versus placebo (all studies)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Rate ratio, exacerbations
requiring systemic
corticosteroids
3 680 Rate Ratio (Random, 95% CI) 0.63 [0.45, 0.88]
2 Time to first exacerbation
requiring systemic
corticosteroids
2 658 Hazard Ratio (Random, 95% CI) 0.69 [0.48, 1.00]
3 People with one or more
exacerbations requiring
systemic corticosteroids
7 933 Odds Ratio (Random, 95% CI) 0.74 [0.49, 1.10]
4 People with one or more
exacerbations requiring
systemic corticosteroids (risk
difference)
7 933 Risk Difference (M-H, Random, 95% CI) -0.01 [-0.04, 0.02]
5 People with one or more
exacerbations requiring ED
visit or hospitalisation or both
7 963 Odds Ratio (Random, 95% CI) 0.39 [0.19, 0.78]
6 ACT/C-ACT score 3 713 Mean Difference (Random, 95% CI) -0.08 [-0.70, 0.54]
7 People with fatal asthma
exacerbation
7 963 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.01, 0.01]
8 FEV1, % predicted 4 387 Mean Difference (Random, 95% CI) 0.48 [-0.93, 1.89]
9 People with one or more serious
adverse event due to any cause
5 879 Odds Ratio (M-H, Random, 95% CI) 1.01 [0.54, 1.89]
10 People with one or more
exacerbation as defined in
primary trials
7 999 Odds Ratio (Random, 95% CI) 0.53 [0.28, 0.99]
11 % eosinophils, lower airway 3 525 Mean Difference (Random, 95% CI) -0.38 [-1.92, 1.15]
12 Peak expiratory flow rate 2 302 Mean Difference (Random, 95% CI) 3.16 [-13.40, 19.72]
13 People with one or more
adverse reactions attributed to
vitamin D
5 879 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.01, 0.01]
14 People withdrawing from trial 9 1093 Odds Ratio (M-H, Random, 95% CI) 1.07 [0.73, 1.58]
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Comparison 2. Vitamin D versus placebo (sensitivity analysis excluding studies at high risk of bias)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 People with one or more
study-defined exacerbation
6 899 Odds Ratio (Random, 95% CI) 0.64 [0.34, 1.21]
2 People withdrawing from trial 7 963 Odds Ratio (M-H, Random, 95% CI) 1.17 [0.73, 1.88]
Analysis 1.1. Comparison 1 Vitamin D versus placebo (all studies), Outcome 1 Rate ratio, exacerbations
requiring systemic corticosteroids.
Review: Vitamin D for the management of asthma
Comparison: 1 Vitamin D versus placebo (all studies)
Outcome: 1 Rate ratio, exacerbations requiring systemic corticosteroids
Study or subgroup Vitamin D Placebo log [Rate Ratio] Rate Ratio Weight Rate Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Castro 2014 201 207 -0.5816 (0.2537) 45.3 % 0.56 [ 0.34, 0.92 ]
Jensen 2016 11 11 -0.3857 (0.4175) 16.7 % 0.68 [ 0.30, 1.54 ]
Martineau 2015 125 125 -0.3535 (0.277) 38.0 % 0.70 [ 0.41, 1.21 ]
Total (95% CI) 337 343 100.0 % 0.63 [ 0.45, 0.88 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.41, df = 2 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 2.71 (P = 0.0068)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours Vitamin D Favours Placebo
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Analysis 1.2. Comparison 1 Vitamin D versus placebo (all studies), Outcome 2 Time to first exacerbation
requiring systemic corticosteroids.
Review: Vitamin D for the management of asthma
Comparison: 1 Vitamin D versus placebo (all studies)
Outcome: 2 Time to first exacerbation requiring systemic corticosteroids
Study or subgroup Vitamin D Placebo log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Castro 2014 201 207 -0.437 (0.2654) 49.9 % 0.65 [ 0.38, 1.09 ]
Martineau 2015 125 125 -0.2925 (0.265) 50.1 % 0.75 [ 0.44, 1.25 ]
Total (95% CI) 326 332 100.0 % 0.69 [ 0.48, 1.00 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.15, df = 1 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 1.94 (P = 0.052)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours vitamin D Favours placebo
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Analysis 1.3. Comparison 1 Vitamin D versus placebo (all studies), Outcome 3 People with one or more
exacerbations requiring systemic corticosteroids.
Review: Vitamin D for the management of asthma
Comparison: 1 Vitamin D versus placebo (all studies)
Outcome: 3 People with one or more exacerbations requiring systemic corticosteroids
Study or subgroup Vitamin D Placebo log [Odds Ratio] Odds Ratio Weight Odds Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Castro 2014 201 207 -0.44 (0.2845) 51.9 % 0.64 [ 0.37, 1.12 ]
Jensen 2016 11 11 0.7419 (0.8715) 5.5 % 2.10 [ 0.38, 11.59 ]
Majak 2009 18 18 0 (0) Not estimable
Majak 2011 24 24 0 (0) Not estimable
Martineau 2015 108 112 -0.3147 (0.3199) 41.0 % 0.73 [ 0.39, 1.37 ]
Tachimoto 2016 54 35 0.6885 (1.6473) 1.5 % 1.99 [ 0.08, 50.26 ]
Urashima 2010 51 59 0 (0) Not estimable
Total (95% CI) 467 466 100.0 % 0.74 [ 0.49, 1.10 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.03, df = 3 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 1.49 (P = 0.14)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours Vitamin D Favours Placebo
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Analysis 1.4. Comparison 1 Vitamin D versus placebo (all studies), Outcome 4 People with one or more
exacerbations requiring systemic corticosteroids (risk difference).
Review: Vitamin D for the management of asthma
Comparison: 1 Vitamin D versus placebo (all studies)
Outcome: 4 People with one or more exacerbations requiring systemic corticosteroids (risk difference)
Study or subgroup Experimental Control
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Castro 2014 24/201 36/207 15.6 % -0.05 [ -0.12, 0.01 ]
Jensen 2016 7/11 5/11 0.6 % 0.18 [ -0.23, 0.59 ]
Majak 2009 0/18 0/18 8.1 % 0.0 [ -0.10, 0.10 ]
Majak 2011 0/24 0/24 12.8 % 0.0 [ -0.08, 0.08 ]
Martineau 2015 26/108 32/112 6.4 % -0.04 [ -0.16, 0.07 ]
Tachimoto 2016 1/54 0/35 20.2 % 0.02 [ -0.04, 0.08 ]
Urashima 2010 0/51 0/59 36.4 % 0.0 [ -0.04, 0.04 ]
Total (95% CI) 467 466 100.0 % -0.01 [ -0.04, 0.02 ]
Total events: 58 (Experimental), 73 (Control)
Heterogeneity: Tau2 = 0.00; Chi2 = 7.59, df = 6 (P = 0.27); I2 =21%
Test for overall effect: Z = 0.42 (P = 0.67)
Test for subgroup differences: Not applicable
-0.2 -0.1 0 0.1 0.2
Favours vitamin D Favours placebo
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Analysis 1.5. Comparison 1 Vitamin D versus placebo (all studies), Outcome 5 People with one or more
exacerbations requiring ED visit or hospitalisation or both.
Review: Vitamin D for the management of asthma
Comparison: 1 Vitamin D versus placebo (all studies)
Outcome: 5 People with one or more exacerbations requiring ED visit or hospitalisation or both
Study or subgroup Vitamin D Placebo log [Odds Ratio] Odds Ratio Weight Odds Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Castro 2014 201 207 -1.194 (0.5806) 38.6 % 0.30 [ 0.10, 0.95 ]
Jensen 2016 11 11 0 (0.8864) 16.6 % 1.00 [ 0.18, 5.68 ]
Majak 2009 (1) 18 18 0 (0) Not estimable
Majak 2011 (2) 24 24 0 (0) Not estimable
Martineau 2015 125 125 -0.9671 (0.6058) 35.4 % 0.38 [ 0.12, 1.25 ]
Tachimoto 2016 54 35 -1.6032 (1.1762) 9.4 % 0.20 [ 0.02, 2.02 ]
Urashima 2010 (3) 51 59 0 (0) Not estimable
Total (95% CI) 484 479 100.0 % 0.39 [ 0.19, 0.78 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.63, df = 3 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 2.65 (P = 0.0081)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Vitamin D Favours Placebo
(1) No events in either arm
(2) No events in either arm
(3) No events in either arm
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Analysis 1.6. Comparison 1 Vitamin D versus placebo (all studies), Outcome 6 ACT/C-ACT score.
Review: Vitamin D for the management of asthma
Comparison: 1 Vitamin D versus placebo (all studies)
Outcome: 6 ACT/C-ACT score
Study or subgroup Vitamin D Placebo Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Random,95% CI IV,Random,95% CI
Castro 2014 201 207 -0.6 (0.4676) 35.6 % -0.60 [ -1.52, 0.32 ]
Martineau 2015 108 111 0 (0.4184) 42.1 % 0.0 [ -0.82, 0.82 ]
Tachimoto 2016 52 34 0.6154 (0.623) 22.2 % 0.62 [ -0.61, 1.84 ]
Total (95% CI) 361 352 100.0 % -0.08 [ -0.70, 0.54 ]
Heterogeneity: Tau2 = 0.06; Chi2 = 2.52, df = 2 (P = 0.28); I2 =21%
Test for overall effect: Z = 0.24 (P = 0.81)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours Vitamin D Favours placebo
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Analysis 1.7. Comparison 1 Vitamin D versus placebo (all studies), Outcome 7 People with fatal asthma
exacerbation.
Review: Vitamin D for the management of asthma
Comparison: 1 Vitamin D versus placebo (all studies)
Outcome: 7 People with fatal asthma exacerbation
Study or subgroup Vitamin D Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Castro 2014 0/201 0/207 65.6 % 0.0 [ -0.01, 0.01 ]
Jensen 2016 0/11 0/11 0.2 % 0.0 [ -0.16, 0.16 ]
Majak 2009 0/18 0/18 0.6 % 0.0 [ -0.10, 0.10 ]
Majak 2011 0/24 0/24 1.0 % 0.0 [ -0.08, 0.08 ]
Martineau 2015 0/125 0/125 24.8 % 0.0 [ -0.02, 0.02 ]
Tachimoto 2016 0/54 0/35 2.9 % 0.0 [ -0.05, 0.05 ]
Urashima 2010 0/51 0/59 4.9 % 0.0 [ -0.04, 0.04 ]
Total (95% CI) 484 479 100.0 % 0.0 [ -0.01, 0.01 ]
Total events: 0 (Vitamin D), 0 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.0, df = 6 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
-0.1 -0.05 0 0.05 0.1
Favours Vitamin D Favours placebo
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Analysis 1.8. Comparison 1 Vitamin D versus placebo (all studies), Outcome 8 FEV1, % predicted.
Review: Vitamin D for the management of asthma
Comparison: 1 Vitamin D versus placebo (all studies)
Outcome: 8 FEV1, % predicted
Study or subgroup Vitamin D Placebo Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Random,95% CI IV,Random,95% CI
Majak 2009 17 17 1.1 (1.1402) 39.9 % 1.10 [ -1.13, 3.33 ]
Majak 2011 24 24 -4.1 (3.3517) 4.6 % -4.10 [ -10.67, 2.47 ]
Martineau 2015 108 111 0.44 (1.4592) 24.4 % 0.44 [ -2.42, 3.30 ]
Tachimoto 2016 52 34 0.4 (1.2921) 31.1 % 0.40 [ -2.13, 2.93 ]
Total (95% CI) 201 186 100.0 % 0.48 [ -0.93, 1.89 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.17, df = 3 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 0.67 (P = 0.50)
Test for subgroup differences: Not applicable
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Analysis 1.9. Comparison 1 Vitamin D versus placebo (all studies), Outcome 9 People with one or more
serious adverse event due to any cause.
Review: Vitamin D for the management of asthma
Comparison: 1 Vitamin D versus placebo (all studies)
Outcome: 9 People with one or more serious adverse event due to any cause
Study or subgroup Vitamin D Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Castro 2014 7/201 10/207 40.5 % 0.71 [ 0.27, 1.91 ]
Jensen 2016 0/11 1/11 3.6 % 0.30 [ 0.01, 8.32 ]
Martineau 2015 12/125 8/125 45.4 % 1.55 [ 0.61, 3.94 ]
Tachimoto 2016 1/54 0/35 3.8 % 1.99 [ 0.08, 50.25 ]
Urashima 2010 1/51 2/59 6.7 % 0.57 [ 0.05, 6.48 ]
Total (95% CI) 442 437 100.0 % 1.01 [ 0.54, 1.89 ]
Total events: 21 (Vitamin D), 21 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.20, df = 4 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 0.02 (P = 0.98)
Test for subgroup differences: Not applicable
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Analysis 1.10. Comparison 1 Vitamin D versus placebo (all studies), Outcome 10 People with one or more
exacerbation as defined in primary trials.
Review: Vitamin D for the management of asthma
Comparison: 1 Vitamin D versus placebo (all studies)
Outcome: 10 People with one or more exacerbation as defined in primary trials
Study or subgroup Vitamin D Placebo log [Odds Ratio] Odds Ratio Weight Odds Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Castro 2014 201 207 -0.3567 (0.2855) 21.4 % 0.70 [ 0.40, 1.22 ]
Jensen 2016 11 11 0.7419 (0.8715) 8.9 % 2.10 [ 0.38, 11.59 ]
Majak 2011 24 24 -1.4424 (0.684) 11.9 % 0.24 [ 0.06, 0.90 ]
Martineau 2015 108 114 0.1823 (0.275) 21.7 % 1.20 [ 0.70, 2.06 ]
Tachimoto 2016 54 35 -0.891 (0.9401) 8.1 % 0.41 [ 0.06, 2.59 ]
Urashima 2010 51 59 -1.8334 (0.7906) 10.1 % 0.16 [ 0.03, 0.75 ]
Yadav 2014 50 50 -1.3499 (0.4272) 17.8 % 0.26 [ 0.11, 0.60 ]
Total (95% CI) 499 500 100.0 % 0.53 [ 0.28, 0.99 ]
Heterogeneity: Tau2 = 0.40; Chi2 = 17.04, df = 6 (P = 0.01); I2 =65%
Test for overall effect: Z = 1.98 (P = 0.047)
Test for subgroup differences: Not applicable
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Analysis 1.11. Comparison 1 Vitamin D versus placebo (all studies), Outcome 11 % eosinophils, lower
airway.
Review: Vitamin D for the management of asthma
Comparison: 1 Vitamin D versus placebo (all studies)
Outcome: 11 % eosinophils, lower airway
Study or subgroup Vitamin D Placebo Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Random,95% CI IV,Random,95% CI
Castro 2014 201 207 -0.52 (0.789) 43.6 % -0.52 [ -2.07, 1.03 ]
Martineau 2015 17 14 -2.55 (1.6128) 18.1 % -2.55 [ -5.71, 0.61 ]
Tachimoto 2016 52 34 0.79 (0.9022) 38.3 % 0.79 [ -0.98, 2.56 ]
Total (95% CI) 270 255 100.0 % -0.38 [ -1.92, 1.15 ]
Heterogeneity: Tau2 = 0.78; Chi2 = 3.48, df = 2 (P = 0.18); I2 =43%
Test for overall effect: Z = 0.49 (P = 0.62)
Test for subgroup differences: Not applicable
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Analysis 1.12. Comparison 1 Vitamin D versus placebo (all studies), Outcome 12 Peak expiratory flow rate.
Review: Vitamin D for the management of asthma
Comparison: 1 Vitamin D versus placebo (all studies)
Outcome: 12 Peak expiratory flow rate
Study or subgroup Vitamin D Placebo Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Random,95% CI IV,Random,95% CI
Martineau 2015 106 110 -5.4 (4.1838) 49.3 % -5.40 [ -13.60, 2.80 ]
Tachimoto 2016 52 34 11.5 (3.6956) 50.7 % 11.50 [ 4.26, 18.74 ]
Total (95% CI) 158 144 100.0 % 3.16 [ -13.40, 19.72 ]
Heterogeneity: Tau2 = 127.22; Chi2 = 9.17, df = 1 (P = 0.002); I2 =89%
Test for overall effect: Z = 0.37 (P = 0.71)
Test for subgroup differences: Not applicable
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Analysis 1.13. Comparison 1 Vitamin D versus placebo (all studies), Outcome 13 People with one or more
adverse reactions attributed to vitamin D.
Review: Vitamin D for the management of asthma
Comparison: 1 Vitamin D versus placebo (all studies)
Outcome: 13 People with one or more adverse reactions attributed to vitamin D
Study or subgroup Vitamin D Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Castro 2014 0/201 0/207 66.8 % 0.0 [ -0.01, 0.01 ]
Jensen 2016 1/11 1/11 0.1 % 0.0 [ -0.24, 0.24 ]
Martineau 2015 0/125 0/125 25.3 % 0.0 [ -0.02, 0.02 ]
Tachimoto 2016 0/54 0/35 2.9 % 0.0 [ -0.05, 0.05 ]
Urashima 2010 0/51 0/59 4.9 % 0.0 [ -0.04, 0.04 ]
Total (95% CI) 442 437 100.0 % 0.0 [ -0.01, 0.01 ]
Total events: 1 (Vitamin D), 1 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.0, df = 4 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 1.14. Comparison 1 Vitamin D versus placebo (all studies), Outcome 14 People withdrawing from
trial.
Review: Vitamin D for the management of asthma
Comparison: 1 Vitamin D versus placebo (all studies)
Outcome: 14 People withdrawing from trial
Study or subgroup Vitamin D Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Castro 2014 22/201 26/207 41.2 % 0.86 [ 0.47, 1.57 ]
Jensen 2016 3/11 1/11 2.5 % 3.75 [ 0.32, 43.31 ]
Lewis 2012 5/15 5/15 6.5 % 1.00 [ 0.22, 4.56 ]
Majak 2009 1/18 1/18 1.8 % 1.00 [ 0.06, 17.33 ]
Majak 2011 0/24 0/24 Not estimable
Martineau 2015 16/125 14/125 25.7 % 1.16 [ 0.54, 2.50 ]
Tachimoto 2016 0/54 0/35 Not estimable
Urashima 2010 8/51 3/59 7.8 % 3.47 [ 0.87, 13.88 ]
Yadav 2014 8/50 10/50 14.3 % 0.76 [ 0.27, 2.12 ]
Total (95% CI) 549 544 100.0 % 1.07 [ 0.73, 1.58 ]
Total events: 63 (Vitamin D), 60 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.80, df = 6 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 0.34 (P = 0.74)
Test for subgroup differences: Not applicable
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Analysis 2.1. Comparison 2 Vitamin D versus placebo (sensitivity analysis excluding studies at high risk of
bias), Outcome 1 People with one or more study-defined exacerbation.
Review: Vitamin D for the management of asthma
Comparison: 2 Vitamin D versus placebo (sensitivity analysis excluding studies at high risk of bias)
Outcome: 1 People with one or more study-defined exacerbation
Study or subgroup Vitamin D Placebo log [Odds Ratio] Odds Ratio Weight Odds Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Castro 2014 201 207 -0.2962 (0.2728) 28.3 % 0.74 [ 0.44, 1.27 ]
Jensen 2016 11 11 0.7419 (0.8715) 9.8 % 2.10 [ 0.38, 11.59 ]
Majak 2011 24 24 -1.4424 (0.684) 13.6 % 0.24 [ 0.06, 0.90 ]
Martineau 2015 108 114 0.1823 (0.275) 28.2 % 1.20 [ 0.70, 2.06 ]
Tachimoto 2016 54 35 -0.891 (0.9401) 8.8 % 0.41 [ 0.06, 2.59 ]
Urashima 2010 51 59 -1.8334 (0.7906) 11.3 % 0.16 [ 0.03, 0.75 ]
Total (95% CI) 449 450 100.0 % 0.64 [ 0.34, 1.21 ]
Heterogeneity: Tau2 = 0.29; Chi2 = 11.30, df = 5 (P = 0.05); I2 =56%
Test for overall effect: Z = 1.37 (P = 0.17)
Test for subgroup differences: Not applicable
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Analysis 2.2. Comparison 2 Vitamin D versus placebo (sensitivity analysis excluding studies at high risk of
bias), Outcome 2 People withdrawing from trial.
Review: Vitamin D for the management of asthma
Comparison: 2 Vitamin D versus placebo (sensitivity analysis excluding studies at high risk of bias)
Outcome: 2 People withdrawing from trial
Study or subgroup Vitamin D Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Castro 2014 22/201 26/207 49.3 % 0.86 [ 0.47, 1.57 ]
Jensen 2016 3/11 1/11 3.7 % 3.75 [ 0.32, 43.31 ]
Majak 2009 1/18 1/18 2.7 % 1.00 [ 0.06, 17.33 ]
Majak 2011 0/24 0/24 Not estimable
Martineau 2015 16/125 14/125 33.2 % 1.16 [ 0.54, 2.50 ]
Tachimoto 2016 0/54 0/35 Not estimable
Urashima 2010 8/51 3/59 11.1 % 3.47 [ 0.87, 13.88 ]
Total (95% CI) 484 479 100.0 % 1.17 [ 0.73, 1.88 ]
Total events: 50 (Vitamin D), 45 (Placebo)
Heterogeneity: Tau2 = 0.02; Chi2 = 4.28, df = 4 (P = 0.37); I2 =7%
Test for overall effect: Z = 0.67 (P = 0.51)
Test for subgroup differences: Not applicable
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A D D I T I O N A L T A B L E S
Table 1. Sensitivity analysis: random-effects versus fixed-effect models
Analysis Random-effects model Fixed-effect model
People with 1 or more exacerbations re-
quiring systemic corticosteroids (risk dif-
ference)
(RD -0.01, 95% CI -0.04 to 0.02) (RD -0.03, 95% CI -0.07 to 0.01)
ACT/C-ACT score (MD -0.08, 95% CI -0.70 to 0.54) (MD -0.09, 95% CI -0.64 to 0.46)
People with 1 or more serious adverse event
due to any cause
(OR 1.01, 95% CI 0.54 to 1.89) (OR 1.00, 95% CI 0.54 to 1.85)
People with 1 or more study-defined exac-
erbation
(OR 0.53, 95% CI 0.28 to 0.99) (OR 0.66, 95% CI 0.48 to 0.91)
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Table 1. Sensitivity analysis: random-effects versus fixed-effect models (Continued)
% eosinophils, lower airway (MD -0.38, 95% CI -1.92 to 1.15) (MD -0.26, 95% CI -1.35 to 0.83)
Peak expiratory flow rate (MD 3.16, 95% CI -13.40 to 19.72) (MD 4.09, 95% CI -1.34 to 9.52)
People withdrawing from the trial (OR 1.07, 95% CI 0.73 to 1.58) (OR 1.09, 95% CI 0.74 to 1.59)
Sensitivity analyses are presented only for those outcomes where results of analyses using random-effects versus fixed-effect models are
non-identical.
Abbreviations: CI, confidence interval; MD, mean difference; OR, odds ratio; RD, risk difference.
Table 2. Definitions of asthma exacerbation used in primary trials
Study Definition
Castro 2014 Meeting criteria for treatment failure and 1 or more of the following:
• failure to respond to rescue algorithm within 48 hours;
• FEV1 of less than 50% of baseline measurement on 2 consecutive measurements;
• FEV1 of less than 40% of predicted level on 2 consecutive measurements;
• use of 16 puffs/day or more of as-needed levalbuterol for 48 hours;
• experiencing an exacerbation of asthma according to physician opinion;
• use of oral or parenteral corticosteroids due to asthma.
Jensen 2016 Exacerbation requiring rescue oral corticosteroids, documented in medical or pharmacy records or both
Lewis 2012 Exacerbation not defined or reported in study manuscript
Majak 2009 Exacerbation not defined or reported in study manuscript; authors confirmed that no exacerbations requiring
systemic corticosteroid treatment occurred in the study
Majak 2011 Reported but not defined in study manuscript; authors confirmed that no exacerbations requiring systemic
corticosteroid treatment occurred in the study
Martineau 2015 Deterioration in asthma resulting in (A) treatmentwith oral corticosteroids, or (B) hospital admissionor emergency
department treatment, or (C) decrease in the morning PEFR to more than 25% below the mean run-in value on
2 or more consecutive days
Tachimoto 2016 Worsening of asthma symptoms prompting a need for a change in asthma treatment (from authors)
Urashima 2010 Asthma attack that included wheezing, improved by inhalation of a beta-stimulant in participants who already
had a diagnosis of asthma; authors confirmed that no exacerbations requiring systemic corticosteroid treatment
occurred in the study
Yadav 2014 Reported but not defined in study manuscript
FEV1, forced expiratory volume in one second; PEFR, peak expiratory flow rate.
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A P P E N D I C E S
Appendix 1. Sources and search methods for the Cochrane Airways Group Specialised Register
(CAGR)
Electronic searches: core databases
Database Frequency of search
CENTRAL (the Cochrane Library) Monthly
MEDLINE (Ovid) Weekly
EMBASE (Ovid) Weekly
PsycINFO (Ovid) Monthly
CINAHL (EBSCO) Monthly
AMED (EBSCO) Monthly
Handsearches: core respiratory conference abstracts
Conference Years searched
AmericanAcademyofAllergy, Asthma and Immunology (AAAAI) 2001 onwards
American Thoracic Society (ATS) 2001 onwards
Asia Pacific Society of Respirology (APSR) 2004 onwards
British Thoracic Society Winter Meeting (BTS) 2000 onwards
Chest Meeting 2003 onwards
European Respiratory Society (ERS) 1992, 1994, 2000 onwards
International PrimaryCareRespiratoryGroupCongress (IPCRG) 2002 onwards
Thoracic Society of Australia and New Zealand (TSANZ) 1999 onwards
MEDLINE search strategy used to identify trials for the CAGR
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Asthma search
1. exp Asthma/
2. asthma$.mp.
3. (antiasthma$ or anti-asthma$).mp.
4. Respiratory Sounds/
5. wheez$.mp.
6. Bronchial Spasm/
7. bronchospas$.mp.
8. (bronch$ adj3 spasm$).mp.
9. bronchoconstrict$.mp.
10. exp Bronchoconstriction/
11. (bronch$ adj3 constrict$).mp.
12. Bronchial Hyperreactivity/
13. Respiratory Hypersensitivity/
14. ((bronchial$ or respiratory or airway$ or lung$) adj3 (hypersensitiv$ or hyperreactiv$ or allerg$ or insufficiency)).mp.
15. ((dust or mite$) adj3 (allerg$ or hypersensitiv$)).mp.
16. or/1-15
Filter to identify RCTs
1. exp “clinical trial [publication type]”/
2. (randomised or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. Animals/
10. Humans/
11. 9 not (9 and 10)
12. 8 not 11
The MEDLINE strategy and RCT filter are adapted to identify trials in other electronic databases.
Appendix 2. Search strategy to retrieve trials from the CAGR
#1 AST:MISC1
#2 MeSH DESCRIPTOR Asthma Explode All
#3 asthma*:ti,ab
#4 #1 or #2 or #3
#5 MeSH DESCRIPTOR Vitamin D Explode All
#6 MeSH DESCRIPTOR Vitamin D Deficiency Explode All
#7 “vitamin d”
#8 #5 or #6 or #7
#9 #4 and #8
(in search line #1, MISC1 refers to the field in the record where the reference has been coded for condition, in this case, asthma)
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C O N T R I B U T I O N S O F A U T H O R S
Adrian RMartineau (ARM) and Chris J Griffiths (CJG) wrote the protocol; Christopher J Cates (CJC), Aziz Sheikh (AS), and Ulugbek
Nurmatov (UN) commented on it. Mitsuyoshi Urashima (MU) and Megan Jensen (MJ) contributed unpublished data. ARM, Alex P
Griffiths (APG), CJC and UN assessed eligibility of trials for inclusion, extracted data, and performed ’Risk of bias’ assessments. ARM
entered data into Review Manager 5.3 for statistical analysis, which CJC cross-checked. ARM drafted the manuscript, and all review
authors critically evaluated it for important intellectual content and gave final approval of the version to be published.
D E C L A R A T I O N S O F I N T E R E S T
ARM, MU, MJ, and CJG all acted as investigators in one or more clinical trials contributing data to this review. The ’Risk of bias’
assessment for the study authored by ARM and CJG was performed independently by UN and CJC (Martineau 2015). For all other
studies, ARM and one of CJC and APG independently assessed the risk of bias for each study. Where data from primary studies
conducted by review authors contributed to a given outcome, the quality of the evidence was assessed by review authors who were not
involved with those primary studies (CJC and AS).
S O U R C E S O F S U P P O R T
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Chris Griffiths
• Christopher Cates, UK.
supported by St George’s, University of London
External sources
• This project was supported by the National Institute for Health Research (NIHR), via Cochrane Infrastructure, Cochrane
Programme Grant, or Cochrane Incentive funding to Cochrane Airways. The views and opinions expressed therein are those of the
authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, NHS, or the Department of Health, UK.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The protocol specified that studies published as abstract only would be included, with a note to the effect that they were pending
definitive evaluation as and when fuller reports became available (Martineau 2015b). In conducting the review, where studies were
published as abstracts only, we contacted the study authors requesting full text of the trial report. Where this was unavailable, we listed
such studies as ’ongoing’.
The protocol specified that exacerbations precipitating emergency department attendance versus hospitalisation would be analysed
separately (Martineau 2015b). However, due to difficulties in differentiating such events, this outcome was pooled in the current
analysis.
The protocol did not specify that we would meta-analyse hazard ratios or that we would use generic inverse variance meta-analysis
(Martineau 2015b); however, we employed both techniques in the review.
The protocol did not specify that risk difference would be calculated for some analyses. This was added so that studies where no events
occurred could be included.
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